var title_f21_39_22128="Scarring in sarcoidosis CT";
var content_f21_39_22128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scarring in sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 233px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADpAWADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5+8VeIdaTxPrCprGoqq3kwAFy4AG8+9Px4yxn7fqWP+v4/wDxVZHiz/katZ/6/Zv/AEM16au1DhQGccbj0/CgDk7DT/HmoXUVtZT6tPPKcJGl6SW+nzVXCeMywAvdTLE7QBfEkn0Hzc17N8Lbry/GGnxraSyzz3CI10tx5flRckpgjB3EDuCcYFes+CPAGl+E9k+ft+rDI+0zAERZPRB/M9TTA+a7f4c/F2e1iuEt9VEcgyvmaoiMR/utICPypx+G3xdGf3Opcf8AUXi/+O19eiV5TIzo6lXKjdglgO4+tISzLgAoDkHJGfwxmgR8h/8ACt/i7gfudS55/wCQvF/8do/4Vv8AFzH+p1L/AMG8X/x2vr5ySwC4AxyAKesLnB+6PegD4+/4Vv8AF3/nhqX/AIN4v/jtA+G/xdPSDU//AAbR/wDx2vsUQoDknP1qWNV6qg59qAPjcfDP4vkDFvqeD/1F4v8A47Tv+FYfGE/8u2p/+DeL/wCO19mGNiSMY7dP1qFElWNElfzXHVwmwH8MnH50AfHP/CsPjB/z76l/4OIv/jtJ/wAKy+MGM/Z9Sx/2F4v/AI7X2V9nmZflXI9vSm+S24s0TdMZx29P50AfG4+GPxgPS31L/wAG8X/x2l/4Vh8Yf+fbUv8Awbxf/Ha+yhIiADaR25FPEqFegwKBnxl/wrH4wY/499S/8HEX/wAdo/4Vh8YP+ffUv/BvF/8AHa+zx5eQfl9KlihSeVU7HqR6UgPiuP4YfGGQsEttSO3r/wATiL/47T/+FV/GPP8Ax76h/wCDqH/49X2kirFbs0fTzCD7gVWxl84/E0AfHA+FHxkP/LtqH/g6h/8Aj1A+FPxkYcWuon/uMw//AB6vsg7mkbare2BTk85cBlbjPamB8aj4U/GUkAWupZP/AFGYf/jtNk+FnxjjQO9rqYUnGf7XiP8A7Vr7ThjcsWVG5/SpnP8Aoyj+82GHpSA+JR8LfjGelrqf/g3i/wDjtH/CrPjHnH2XUz9NXi/+O19sEjjH0pjyqvI/CgD4p/4Vd8YsZ+zanj1/teL/AOO0f8Ku+MP/AD7al/4OIv8A47X2c0qlMKCcnPFNzJnOzj3pgfGn/CrvjFnH2bUv/BxF/wDHaP8AhVvxj4/0bUuf+oxF/wDHa+ytzENlUwe/pTkjZlJWTp1osK58Z/8ACrvjFx/o2pc/9RiL/wCO0n/CrvjF/wA+2pf+DiL/AOO19hXGoWludlxfWiMOzyqD/Olgu7edv3V1A59I5VI/nRYZ8eN8L/jEvW21If8AcYi/+O0z/hWfxf8A+ffU/wDwbxf/AB2vs5g4UDPHbIoWRtpEijj17+9Aj4xX4Z/F8k4t9SOOv/E3i/8AjtL/AMKy+L//AD76l/4N4v8A47X2aBC5wBg+1Ne3YDCHPFAHxp/wrL4v4/499S/8G8X/AMdo/wCFZfGD/n31L/wbxf8Ax2vsNgyuAwIB9utOBPPoaAPjtfhj8YGOBb6l/wCDiIf+1axfE3hf4l+GGiGujV7RZeEkN+HjJ9N6uVz7Zr7dBxjHPtSziC9sZbLULeK7spRh4ZV3KRQB8ElfGQ/5ftS/8Dz/APF05I/Gjhyt9qR2DJ/0/t/33XvfxL+GE2giXVvDge60UAtLb8tLae/+0n6ivNEfBSWJlz95COQf8aBnGAeMcZF/qWP+v8//ABVM8K+IdafxPo6vrGosrXkIINy5BG8e9d1cKpHnR42N1X+63p9PSvMfCf8AyNWjf9fsP/oYpAHiz/katZ/6/Zv/AEM1654e0a98Qavb6ZpcYe5m5yfuxIOrt7CvI/Fn/I1az/1+zf8AoZr7a+GvhRfC2hk3Cj+173El046xr1WIH0Hf3pgO0Tw3YeEnsotLsZL9hA3mSuR+9mV0fe2RhTgHYfbHGa6gcE9SM4HFOA69++KACxbKnaMfMBnrQITBLAAZI7AVKtuQCXIUe1XLW1aTKxcAfekPSrSJFBIojjNxMx+8eR+VAFOGGRsfZ4GOP4ug/Okkt50YibagA3HB4UepNZ3i3xlpHhGHdrV0JtQIzFYwNlz7kdh7mvBPHHxB1fxXK0bt9i0/tbwsfn93Pf6dKAPTfFfxQ0TRJJLbTYzqt6vB8tsRIfdu/wBBXmusfE/xPqRPl3MVhGeAtsmD+LHmuKVQoCgBR0xS4oGaM+v6zcHE+r38n1naqbXNyzZe6uTnv5zf41H6UoHpQBYS/vYwPLvrtfcTN/jVy18Qa3avm31jUEI9J2rMHXvTh1xjkUAemeBPidqMOq29l4nn+16bM2z7SwAkhY9GJHVf5V7cy7JGCBpBjOQOMV8iyAGKQEcEGu28aeLdXuUsNKS8lgtrSyhjkWJipkfYCSx6ntxQI931nVNP0W0S41e6htIHyELty59gOTXMN8UPC6EhL2544BFu2K+fnd5CpkeSTb93exbH0zSjjrQB9E2/xJ8NMixrqyhc5xLEy9fwrqNM1mDVLYz6XcWl3GByYiGI+or5Oxkc9RV3R9SvNE1CO+0qdoLmNgQV6MPRh3B6UDPq03kpQo2wqRgrt4x6U0X10AArBVAwAB0FZPhvWoPEOh2mqQKFE6/vEH8Eg+8v4GtFQWAGeKBEwv7rdw/5jNNnuZ5Tl9q+w4pRgBVVefX1qJlDN8xJFAESuz7SGz346VYV2XBwCR6DtT4hhKcAFyBQMrEyDgEAUjA7Rlicd6tld2eO1NKqV6FT1APagVissZZlQfePQV4j8V/Hk2pXk2jaJM0OmwMUmmRsNcOOvI6KD+dep/EfWv8AhHvCV7exHFxIvkQZ/wCejcZ/AZNfMIUgDnJ9fX3oGV5YkkOZUEnu3J/WkWNYv9WDGR/cJX+VWDg8/wCfwpjdBnoOlAGponivxBoT7tL1a5UZyYpmMsbfVW/oRXsngf4saVrMUdn4k8vSdTJ2rJkmCb0w38J9jXgZGRzwKRgGGG6dMYoA+0NO8i5t2EQgnIPySK4YN7ZHQ1IIYS2xGe3l/uPyPwr5I8Ianq+m6iToc1ys6o0pjhbIIUZJKnggCvb9C+MOl3Hh6wn16CRrl28uX7Mu4qQMl8dQpoA9DnhljVhJHlem5eRVN4EZcqdp6cdKt6FqVnq+nJf+H7+O9tXGRtbJGfUdj7GrE8EcrkQgRXIGSh4D/wD16AMV0dCCwxz+FHXrx3q7yVPHJ6g9vaopYBjMfJ7igRHBIyNkYz0O7oQex9a8J+MvgJNDkbxDoUO3R5nxeQL0tJCfvD0Rj+Rr3RhhgrHB6c+tK6Q3MM1veRLLZ3CGOaFhw6nqKAPjyNvLfO0Mp4ZezCvM/Cf/ACNWjf8AX7D/AOhivbPHvheXwf4lm0wlpLN18+xnbnzIT6+69D+HrXifhP8A5GrRv+v2H/0MUhh4s/5GrWf+v2b/ANDNfoMSS2W7nJFfnz4s/wCRq1n/AK/Zv/QzX6Bq4CknJGM7QMkj6U0Jk0aFmCDqRkn2q3tCqFTp14/nUdttECv8wDDdyCCB/SpXkit7aa4upVit4kMkkjHhVHJJoAumS2j00SyXcUFtEhaV3IAHqTmvFfHvxdZhLpngk+Rb8h9SYZd/+uYPQf7R/CuM+IHji58VXbQWxe30SNiIYM4M2D99/XPYdq5Ef59qBjpWaWd5pnaWaQ7nkdizMfUk9aaeeM0Yx0xQTjr2oAOpPp6Ufp7000FuhIzQA7v2/CjueOfSm+uPrS5wef8A9VADgT2/z7U4EED0pv60q9c9PegCzp8H2u/tbbODNKkefYkZqxrNwt1rN/PHkxvO2zP90cD9BS6ATFfSXmMrZwvNz0zjC/qRVBMhQD17mgB46Yp31pimnj880AApe59TSDkU5evH69qAPZPgLcmTRtasmzthuElQem5cH9RXpyjYuOpJyfavKvgBE3l6/cYO3MMQPvgmvV2P0/xoAN2Ouc9KRWAUMeg/lUe7L9e1Oi+YAjvQImBwAfXnHrTgcjrjv9aiU9+c04ZJ6d880DJQ3BJ71LHg8Y471BwWJxjvU0ROV/OgDyz9odWHhrQgD8n2x8j/AIAcV4UffoOK+gv2grYyeCrWYDP2a/Un2DKwr58/OgBG6c9aYfpzTyTz2prDjgcmgBh6EgcU08nNOI5xn8u1J644FAD7W5uLG6hu7KQxXMDiSM54yOx9j0NbPiFrM3cN9osU1vbX0S3Jgc/Kjnh1X2zn86w8Yq7YRTXY8qLLyRZaNM9u4FAFvSNVn0PU0vtBvJ9Mu8nfg7o5PQMvevcvAXxgsNZlhsfE8UFjqmQI5w37iY9sE/dJ9DXz5HIVcSp98MCM8gfUVHcxq+9J0UAkhlA4+goA+ybgO0zsygOfmGDx+dN5DgKPcHHWvCfhJ8SJNJuLfQPEcxk0yVvLt7uRstbseAjE9VJ4B7V708ZRyvpyOetAFWaPP7wKMjqKrg8ZzjmrzgqSWYtGRgg4qqRtJHpQI5b4meF/+Eu8KT2tuoOq2WbixcjksB80f0YcV8LeE/8AkatG/wCv2H/0MV+iKuyOGUlWByDX53eE/wDkatG/6/Yf/QxQxh4s/wCRq1n/AK/Zv/QzX6DwjfJgEk4xzxivz48Wf8jVrP8A1+zf+hmv0JibaFRBuduKEIsSNlgAMg/zrx/45+LJjMvhexbZCgWW+dTjeTysf0HU/hXrU8qWcc11IG8q3ieVmI4O1c4zXyVc3s2pXVxqF07PcXcjTuzdcscgfgMD8KAEGO1Kfz70zOadnB4PPWgYuecdqQ/r7UmR26980n0NAC849aTtntSZ5zSjHrQAo/I0ueuab7j8KUeo6UAP/lSj1pi9unFOclVyFyccY7ntQBqRyC38NTIB+8v7gDPcRx88fVj+lZ+a2vGVh/ZGsxaVv3NZ2sSuP7sjLucfmaxD04oAeDnGP1p1R+gFP/nQA/vQCByeg5pua3PBGiN4j8VafpuD5Dv5k5HaJeW/w/GgD2z4Vaa+keBrPzBtmvXN24PBAbhR+X866s884JNSuqK42KFVcBVHQLjAFMGRjdye59TQIjwdmUGM9CadFvijAYDI7jvSn19PWlB4A7enpQA/POe+MZpw57nj9ahzkHPWng+vPA6UASr0PINSxkgjPTtVcZxgce46VMD82MflQM5T4wW32z4b6wB1iCXAHrtYf0r5lJwcDivrfxNbC+8M6zbHnfYSj9M18ixN5kET/wB5Af0oAXPOTSZPPof1o9sUnJ7c4oAQDPOO9B74ORSdv8aQnrxQApxwB071c0idIp7hZUZxLbvGmzgo/VWH0IqkcjrU+nsRfRkEjAY5HXGDQAuVcbXwm8ct6mldhLMW/iIA5GAcU1FWTyzGeSvzA9jRLIbiaGNCM7QgA45FAEM0ayoY3XG7IYHpivpL4IeIz4m8MRWN/KW1HSnFrMxPzSx7cxt+QwfcV85Er5BSRP3isRuB6/Wum+FfiUeFPHNjezSbLG8ZbK7z0Csfkc/Rj+tAH1NNbxShpLRmYxkq0R9M4OPyrOmXZIuCcEHaf6VuXLm1uVf5Qjnknvx0/rVXUrdRh04jk5xjo3/16AMkHoO3v0r88PCf/I1aN/1+w/8AoYr9Djzn1HpX54+E/wDkatG/6/Yf/QxQxIPFn/I1az/1+zf+hmv0S0y1ErbpSAijLt0x7V+dviz/AJGrWf8Ar9m/9DNfo5e5t7COBcl3+9jqW9KQznPihqQi+GHidiBCgtfJiC8Hc3yjH518rdOK9x/aM1Q2mjaN4dR/31xKb65UdkT7oz7sf0NeGnrTAfmim0tACk569u9BwR/Oj9aOpoAT+dLnmj1o4xQA4ZzSj9KaPxp35c0AKB9K6P4e6Yup+MdKW4iL2UE63FwduRtT5sH8QKxNMsbvVNQgsNOhaa8uH2RIDjJ9T6CvUPEdxD4L0KLwzphh+3TRGK8uh1MhH7wg+3CigDzjX76TVdd1HU5W3G9uJJgf9kscD8ABVEdsVfgjikhmhlO5Y0JjdPvKw6cdwafr9l9gls7dHSQG1SUsp6lskj8DxQBngDGOlOHvTQSF56inUALXtnwJ0I2WlXmvXC4lvv8AR7bPaNT8zfif5V5h4J8M3PirW47OIMlohDXU46RJ/iegFfS6RQ2drDb2kYjt4VEcSDoqrwKAH5weOtMPGe+OaazYJHI4zn1pGOAR3oEOznNHQ89cdKbnHB70E4JB9KAHg8464yKcDnp1A/Oq9u25WB+7u/WpWY4zxmgCVTyBUitz3z1qvnGcZHFCS5bA6Dk0ATOonWZH4WaNovwII/rXyLc2klhcz2M6+XLayNC6nqNpx/KvqbxDrmm6HpE1/qcjJDFgYTqWY4AH415H8RtCg8RWtt4r0MFLi7X9/Yn/AFs2OBIq/wB7HUdxzQM8tbHOKaSeMHH0pWJDMpGwrwVPBB9/emtk8k0AIcfjSH60UmeKAFPtV3R4GnmmaONnZIz8i8k54P6VQU72wuGJO3A9a6bQtQs9JzG8UjkhvPkR9rFiOAD6DigDU+GVnpkfiOYa7IvlXVpLDCG/gkxwT6H0qp8QdCOhXunqYWh+02ySIqrjhQAxz7nn8ayPEmpRa7qEVzDp8VlIIVikETkiUjPzkdjjriq6314wsluLia5hsjiITsXEYzkqM9iRQBTf5mYscKwyOam1R7S8BRIHjjEaxYzw2Bgsfc0lzIsl1NNGqxI7l1jHITJ6fSoRj5tw4I6igD6L+BvjtPEOjN4e1yTfqunxjbI3/LxD0Vs/3h0P5969QuNi6ZIEkDqB8jZ5z6V8YaTq1z4e1ay1jSHYXdmPM2kcOP409wR/SvrfS7yHUdOtNQt8eRdxJOoz03DOKAC6TBV1PXrX51eE/wDkatG/6/Yf/QxX6NuN0ZUEgnjn+dfnJ4T/AORq0b/r9h/9DFIA8Wf8jVrP/X7N/wChmv0gF9ZkK8kb70BJyuApAyTn+tfm/wCLP+Rq1n/r9m/9DNfd3xCvW0zwB4hvYhmQWhQc9C+Fz+RoA+fPHniKTxT4u1HVXz5Lv5Vuv92JOF/Pk/jWFmkRQiKo5CjFKB/kimAoI7UtH4UduaAFopKX60AKOlKOnrmm9h+tHegB+eeo+tS28MlxKIoR8x6k9APU+1FtA87FU7c47n2Hqa6aOy01Lm106e/FgvltJezEb9hAyF9z7etAEuhXFvYalpdvocsserG5Um7bG2Q4OQO4A5+tVPEE11e+Ib6W4LOzScDvgd/bPWuy0nw6NH8F65qzCJL66aKOxjmAMtvCzcSMP4WcZPsKpGwtLYQKyG4upzuJLZ4PAAPrQI5mcTJbRwm3g3RHzPMVcu3TAJqlfu7FvtbtIWJbdjleeceldjqumvYtEZP+Ppl2quNwHPAPoQPWqOhaq2heIFj08RXX7p0vGliD/Lgkhc+hxzTAxLbw1qt3ph1G3tm/s4feuJSEUfnW/wCDPATeIHaWbVrJLSM/vEgffL9MdvrWVNq+o6/qgN1dszTgQrETiHGOFK9BzUvgYXS+LLBbCQ29z5uJOMAoPvAikB714e0200fTRp+kxJDbA5Y/xOfVj3NaTsx6tnJ4HoKgiA5wPlLZ604tk/pQA0uYflbBQ9P9miTMkLLHKyEjh0xkfnUUzAMoPO3tUAdlJKkZ/lQBfQttUMdzYAJIwD+FDSgZAOccGqiASLl2YtnpmnOcEDoOaAJo5ME4x689qfuI+8eDnmqSZWQgE5xUqozADHXtQBOZGJwpOKljAVQDz7etV1ypz3zU0fvxQBx3xd1ZdL8IgRW1tLLPcLCFmTcNuCSfqMcV5VoeoxQJe5urtdQuYFKvJ92PaeGU/wAJxxXc/G/c+maIN42PdyYB4AITjmuEltryGws7mzcSRTB4Li3GGCEck+wPWgC9dafY6zFDFeyn+0mOPtypguuOA47/AF61yOuaNeaQyG5VZLaXmK5i5R/x7H2NdZ4A0ufW/FNpaXMk0Ns29hMp+UsvKq3ua0dKklvL+60+8iQxyTSJJaOAArLnBx65HWmB5dn1OaVQWwAMknArqNY0SIxPdaMCVkOVgdf4RwSD+fFc/E5KFdwUk8HsD6GkMfH5lk8sXkr9pPBLDmP6e/vT5kt5RZwWUcySGP8AftK4Id89V9BjA5q5bSQ2+qx3Ov20lzhcmJmK+cMYznvj1qSbSrK8WM6FPMSzFRb3WAQc9n7j60AY0mY2JK7Npx7jFTxQBx5qRvJAqh5jHxtGef8A9fvWhd6ReaRfNa6jGYp1CyYYbgoPQ+4r0fQPEWhX3hx7a9+yWeqTwSJMwiCp8xxz+WaAPKNUa3e+uH05XismbMUcrZdV44J71XiEbFt7EADIUd/arOqae1hdtCpSRDkxvGdysvYg1WiiMiSHcAyLuUDqxz0oAjwCMkj0x619KfBO/e/+GGlee3zWjy2eT/dRyF/TFfNzsC7MqhBjG1a+g/gJC5+G0EQT95Ne3DDnqN/X9KAPRM88EdK/OTwn/wAjVo3/AF+w/wDoYr9GriF7aaNXYNvU4Zehx2r85fCf/I1aN/1+w/8AoYoAPFn/ACNWs/8AX7N/6Ga++tb0uLXvCuoaRKwjS8tPLDv0RsAqSfY4r4F8Wf8AI1az/wBfs3/oZr7b+JhaT4U64bdnDJbRsSpIOwEZ9+lID52vrS502+uNP1KEwX1u2yWM9j6g91PY0wYOe9aFrfRXUMVjrckzWiH9zeL801r+fLx+qnp2qte2cljMscrxyxvzFcRcxzL2ZT/TqKYEI6dKX+dJTxG5j37SEPG4jigBoozg9atNZypAk/kubdztWYghC3oD3NW9F0u+1i/Sw0qIXF055QJwo/vFuwoAzI43cZVTgdT2FbPhrw5feIJZBYIphh5muZW2QxDvlu/0r1Hwv8JYbd/P8T3P2+TqltASsa/7x6n+Vd7eaVp02inSZIbeHS5Pk+zxkIrH+poA8L1GWx0zTIrTQC17cFjHJfmPBZmP3YV6/jXdeB/hpaQ2EF74pt/O1AyiZYPMO1VHIDjue5rsdG8NaLoshk0/Tokn/hlc7mX6Z6VrMpY9wTz1oEUtV0TS9V+2G9ttzXTI0jqSGJQYX6YFcfqXguw0XTEvl1W/Mdm4kIChnIB7D+tXvFPj3TvD13JaRxvf30fEkMTYWPj+I/4V5prviiXWdSivZr+6s5BHLCsLR7o0jccgbeucdTQBa8eeK0ub2XTNCEi2fAecfNLcMece3JxxUOq6FqOieG7u/vUUX955Vt5EA3PbwY3FnA+6WwB+da/hPw/aWmnQ61p5jv3nt5WtbiZhELa4UYClSfvZ6Vc+FWl65b65eXupRzwQSQ+XMZzkyvnI+vegDkvA/hTU9e1C2mhiaDT4pFaS4f5RgHOFHc16rofhO10TUZ9SEhe9mLqGHRVY56V04kwgB+6OgHFRTsoQtjlqAHRsyxjKng5oeQ/dUjNBkwPao8jrjr1xQA143O75uvU0bDnr19BSk/h2yaUnrz19aAFUcYPAz+dJuIY89DQzhAPXBqDO5SQTx6etAE8bAZz0z0qxG2csTuJz+VUIYyzZY9O1WNu3uc560AWwSRk8H9KUSRojGZwiKpLN/dAHJNVwSOW6Y61y/wARL9bbwpqA3yIsu2AunXDHn9KAOf8AF+taJ4v8PXFvZC5ha0nWaOaRRnAO1mC/3SDXK6P4enS9litJ/ORdwkZFIbpgAj39alsyYYbDeZIjdoUijaLLtETtyPxwa1/LktDMYNWRpbAhLpogUMTp/fHpimAmlxC1ubOe32Wt1byB2MhO0uvBH1rdTQ21qLV/E0GyMqDcRMsgJd1B3gDqpG38c1F9kvNcdWn0tN8iCbzkcAO3096p6N4i03R1u9GupLuzillYSMItwVj1oAz4tOu9W0ldSjtpTAVF4qRcsEIBXA+pJNcPq1v9oMt/bQoqYPmBT97nBYDt716PYabaRyXF34d18K0YIaJHKbFHTCntWONDufMle5S2jlKNK74wjr1wMcHNAHFNdXF7osFveTLIlrJi2RwAyoRlgD6VWYMANrnYM4H8WKvajpYgnaWKKZrV/nKAfPGOn5e9Cx291YxCzEw1NAwmWQDZ5ajIdT6+oNIY2W4up3P26e43tEoVrkHLKo4Az29KhjVRbuAmWcAK2c7fWux+G9zJqvivTxrStqFpDGyq7sD5eB8vXqOcYrufG3hG3ufF1texwJb2CWgkuBCOSA2PlXuSP5UCPE0t2intI/MCGR8IegXJxzVO+hltdQuLe5jaK4gkMbqeoI6/h3rqfHMFvLrch0qXdaNGoj+XaV9AQe9YmpXBvZhcTQybpLTEznJCyrwGz6HpzQMyXYRQNIFJ2qS2e49q+pvhTZpo/wALNOCMXeZd5fGP9Yd3H518qTxSXDCzRJPNuAIoxtJzuIB2+uM5OK+zdItY7bw4+nK6olmqRhiOBtVef0oAsz4bSEK/8sWU/QdP61+b/hP/AJGrRv8Ar9h/9DFfo3FL5mm3YRf3Sj5D3Y561+cnhP8A5GrRv+v2H/0MUgDxZ/yNWs/9fs3/AKGa/Qe40u31Lw/cWscRHnWfkyRdd6smARmvz48Wf8jVrP8A1+zf+hmv0I8PSEtp7iThoEwvblQeKAPkRI3iDQy582JmifP95SVP6g1btb6SzheNolubMnfJbSfdb3U/wt7iug+KumjSviT4gt0G2OSZblAOgDqDj881yzbtpCLuc8Ko6k9hTA7jxP4Ek0PQrXxFYXQv9GuBG22RdssIkHG7HBAOBmuPSVQqiUu6qeFzwK+odH0WJPB2m6BqUQuIvsSW9xE/O7jkH6ZrznwT4XsPEfiy61GSxW08P6ZOba1tQmBJIhxlieW5GT+FAjB8K+CvEPiKCCG8aWz0m2bfGtyDtyfvbV9T616hdvo3wx8GzPAivKoJjjZgJbuU9B64/kK8+8cfE/xFFruo6bp6QabHaTtDkJvkYDuSeB615rf3l1qN291qFzNc3DdZJW3H/wCt+FAHRat8QPFWqJJ9o1GS3t5gUKWybIwD/DuxnP41H8OtPm1TxlpcZEs0FvL58pZ2KxqueTzwM4qpYeJbvT/CWq6CY7eTTtQYNukX5oX4yUPvgV1Xwm0S9j8Ui4v7e+tLWO3MmXiKpMCQACfTv+FAz3Fsu5OAB9axIvFmjyeJ38Ox3Uh1MEpt8s7Q2M7d3TOOa2FdGXfDtkIPVDmvF9S8U+HtO+JVrr+nwXNyVldb9uinjZujHcjr70CNrWdFutOlu7Hw/wCFmnnmdjNqFyfMMu7kkEnj0rJj+Ht7fWF21oJ4bq3ZFjS9ICyKR8yjHQg16Rqen2HiaG0k3SS2DJ50U0MzRyKeoxjsR61BqWh3cqRf2Zr1/ZSRpsy5Eob3IPf3oA8k8QaBqmkWEen6lAyafATOHHMbOepzXVfBvU9SvLqbTzK8umW0RbLnPlsTwM/0rudKtNXt7SaDXdQtdVjYYTEAQ47huxq1YQW1lGYrG3htoy2WWJcc+9AFyRSyMAxUkY3LyR71B5Y8wHeT9alDc+gPX3ppAPfB6YzQApY9R9RTD1Gep5+tBPOT/wDWpqnIyDk+tAD85yfams6pwD83pTQD34xTkC4ywJzQBFskdwQRyc/WnlXXhQAPSn7iGXb0/pTh06n1oAhQMCCTjt61bMgMYViMjPT+tMChxnkcZNSWaGS5EEgDRuDzjlaAIZZQAUQVx3xHAn0eyt1cK811wOm4qpOM1219ZG2KbyTnOCP61xnxL8hvBzGaMGVLqJkkP8Bzgn8qAOee3uPElha6pZr+8sE8kqhIMbjipdNeTR9ZuLPUoILi5vLRlu02kNMy/cYnpg5wai8CeIbez1mWF5I0guj5RkB259CwPGfeu/bw3bC6E0l41yWhaIxykHIP8WaYGJ4ittQsvDkOqaE8Nrc2LI1zZv8AOhQrygI6ECuN03SYtRuLe5nMzrd7kjigmDmFzkhjnkrW/wCLNQ1jQJkg05IJtOcADYm5ZSOze9LpvhBNdM15FbTaRdqBLDCWwrN3CntQByFzot/ZgxXUcQussqlWADDr+fFX4dU1OZxKIUWxm/d3EchyBwBu/wBk1QntysssE2mX010TsLQvuZnz6DoRW5oZ+xSyWV7bFjKpWcMNuMc5b3oAzNUktWktZJo7uSyhTaphcKw55VqfBqukLfAa3oSSWQXcJInKzxRnof8Aa+lSXDwz24hjjkljdvmmhGGjVV4baetZYsGa1F/Y3kd3LOrW3kXK7ZE9Cp6fSgDqZvAOjNazapp3iEv4eaPdEqj95CzYHJqHw488l1qCeIWvLwaCBJbXcD5AjY4YcfeHAODTPBcxsTf2GqwvNbLEHuLVgA75ODhe+K9F8O2OlRadcQaQqi1nyrR7SpCkdDn2pAeOfEudL3xRqTSxrazwIjRiIfJcLxg59SDmjR/DUvh/wjPrPiG8lt9P1OF4LqwK5PlsD5WPSQt6V6HD4RhvriOTxTZRQyafMtvp0scpBuYV5XeO546e1dD4s0zTNf0pNN13i0a4SRcPtJcHgA0AeffAFpxb66NnmaXatH9llmQF1mK/PtPpjGcd69b0e6W3e4W5QvDOADjnn3/Cs/StJsdF0safpUCQWcZZginPJOST71JFnaoUncTnP0oA2Lu5t3tTHaqVLkIQRgAA5NfnR4T/AORq0b/r9h/9DFfoLGcysSCNowPzr8+vCf8AyNWjf9fsP/oYoGHiz/katZ/6/Zv/AEM1+g3hq1IttPmCsQsEZLMMcmMV+fPiz/katZ/6/Zv/AEM197aVezz6PYOZXVPssO3HCkeWucfShAcH8X/CN94k17+1dDSOedB9mnhLbWdV+6yk9SMkEVR+Hvw1ubXU4dU8TKka27b4bNW3FnHRnI7Drj1r0cNHvYIyFlI3BWyQfcdq0NwUB8k5I6c9Tjt9aBEocs5OSTuzmsnxXqzeGvCl/qkEMbSQLmGJ/lR5GOB9eTmtPBHKk/lnNeV/H5JFg0Bw7+Q8koZAeN+0YP5CgDynULy51LULi+v5fNu7iQySvjGWPoOwquRmlx7GjA/yKBmv4T1r/hH9ZS9awttQiK7JLe4GQRkHIPZhjg16/wCAPHt14o8QapZT2cjW7lZLWMYb7PHwGDHvzz+OK8IHtUtvPPbyrNazywzIQVkiYqwIOeooA9u8YeNIfAfiSHSrHTI5bdlF3OzyEF95PCflXil5IlxeXM8aCKOaV5VjByFDMTjPtmvSbH4kJqD6RF4g06xurtpxbT3dxACkcDHG4D1zjPbvTPi34Mg0/UIr/wAM2he0kVhdQWx3iBx0YKOQCKBGfp/xJ1PTtBtLC0s7QS26LGtw+WyB6r06V6h4R15/EWix38to1rKTtlUD5Cw7qe6mvC/DGjT+I9SSwtZY45CC+984AHWvdvBGnJovhwaWLh55rWZg7ngHdzwP7tAG0eB93PvUe3ngA57jtTmIA2sKaGbaMfXnpQABSWwmcmuO174i6Xpmoz2S2dxeSQN5bujBV3dwD3rotd1yDQtJmvZI5JpcbYo4l3FnPQewrxCHwr4iu2D/ANlXReYl9zAKCSc5OaAPRbH4n6NKwjvbO7tU6b+JAPc45rs7ea3uoFntZUlhcZDIcgg15Vpvwx1Ocq2qXdvZxdGVD5j/AOGa9Q02wtdLs4bOwQiOMADceT70AWePpk0c57gfXNG7J7/hTdyhgFzmgCTA9TnrS9OOlRCRcEv8tSD+91zyKAHMWGNowB196kWV0ZSkjKc9qjXnoeKeCdvUYz60ASyXLvMHkbe2MZA7VU1XTLTV9OntLpd9tcDDr3HoR6EVYIycqeR2xSlDxjI/GgDyY+EUguNS0vV0K5VZrbURwuBwA39RUXh7S9Yi8daTB9qlU2v+tlwSjwP2r1G+s4r2E295CssTdVPeo9JsU025d4hI25dn71txUZ6A+lAGN4C8OXPhM6zBczrqJvLkSKzk7I0yeQD3x1rqyqEnYTgfl+FOIRlJ+6KhwN3ygdehoA4f4kQXmk3dj4p8PM0N/bvi6QDKzJ6sB+tZer6r/b2oWurqiWc726icDJUEdQfUc9a9RAi5EkSEkYJK1mXmjaS9rKGjigUqQWTgr9KAOEl1KO5WWJbFEUpsCoOSQ3LAj1FYkOoR2+obJbZFaR8wRyg8nPC/WvQ9I8Q6HDttrRDM6Eq8yx5wR6mtq4gtNSt2mhS2e4Ck27vGCEk/hY/Q0wMjS/D9zLdz6troWeZXEkHy7GjQLyMjr9DXQzTBEBhgLyMu5Ix8pbjpntXKaBb674d0fVdX8Z66+qvCrTJDbx8IoHQADkk1Y8I3Vx4itNP8Q6ppr2N8oYJCSVKg8HIPX24pAdDFEbqOGXVVVHjxMEYgrAwHXP0zzXkviPxnJqEfiLVLZkNjbzR2Okrjgyjl5j68f0rpfjP4m/srQoNNtJhHfamWV/VYAPmPtngZ968s0jQ9X8Q+G9PttGsWmtYLidzKBsj3HAABPXAGKAOx+COqXl1f6jp9zNPcRLH5/nOSxBJIIr1dF2Io5z2Nct8OPDH/AAi2kSC5Kvf3DbpmXoPRc+1dUWVzwflz24oAch+eTnvivz98J/8AI1aN/wBfsP8A6GK/QFcEvg4yT+Ffn94T/wCRq0b/AK/Yf/QxQwQeLP8AkatZ/wCv2b/0M193+HWB0TT8kt/o0XJ/3BXwh4s/5GrWf+v2b/0M191eH8jQNHY5wLSMHj/ZFCBmmIw0RXuvTjtUsfzRKGweOmKijyHK4PT1qTPOPbtQBKMMPSvMfj7Kw0/QYBH+6aeWTze24KBt/LJr0sHHWs/XtEs/EdpHaarFvtUmWXajlTlc9D268+ooA+YyOaQj0zXQeOLDRdM8QzWnh68e5t4/9ZvIYI/91W/iFc+Qf/1UDGkUeval7ZP5Zoxx9KABXxkN90jB716p4C8PXmi+JNA1K6huLptThd1eN/lhUp8rMc/Nkce1eVYPWvZvghrb3ulTaLdSAtpuZbcsfm8ljyo/3T+hFAHS2PhjS9O8WnWbWBre4aN0dIziMlhy23pn6VqWcax6jcTStHHaCPhm42knkk1bvVkNsRaRRtIWHEp4Ck8n64ryv4z3VyYbC1hMq2Ds3mFeEkYAYB/U4oEepTr0MbCRT91hyGFcvd+OvD9nqz6bd3E0csbbHn8omJG9Cf61x3ws8WJaRT6dq995cEQElvJKSQo7rmsT4na9Y654gibSgDa20ZjMgGBK5OWYe3bJoA9sjaOWNHtzFLCw3JIjBlYeoNOLHqxY/Q1zvwqsynw/01vM3NO8koyeApY4Ue1dOUYZ9KAIznvznpSEAr82M96fjH/66YcF891z7UARygGI9QcdvWmRRSlMcLnHGKvwwjyhcTrnn92nr7mrCyTZk2kKqjOBxz6CgDIYtGirImVz1q3wAPpxmrb7J41W4Ubiud6rjbz3qr5bREI/XHB7EetACrn26elPGSB04PpTRn6/jUqKcYOfWgBUTfgLkM1VYNQsbi4ltob21mnjO10SUFlPpjPWqPjfXU8N+F7q93L9rkUw2qHq0hHB+g6mvm6JDGQwdlkJ3GQNhic5JyO9AH1Yqsr5dQpHX6Vzfj3xC3he2tJ/7NmvrW4cpI0TYMeBkV5v4N+JWpaS8dprj/2jpuR+8k/1sK9+f4h7GvaJbyw2Wkc91bg3g3W6SEfvOMjbnqcUAc3N458OWmmWl3d3UkbToGW3EZMuPde1XPC3iPSvFMM8mjzFpIGxLBKu2RR2OD2PrXN/E7wLJrFml5otsDq0BCmLdt86PuPqO35VxXhbwj410nxBYahaWr2Lo4WV5HGDF/ErKOoNAHonxG8bN4MtLNotPF1LdMyhpW2xJgZwT61H4V1W38eaJJM9rc6dMp2twdhb1Un7wruZBBdIsd1bwyKfmMciBlB/GpTGqIBEixwgcKoAGKAOL0rwfdW0U0V48fkFyUkh4JH07Vs2WhwWpBjMzlBwGfikv/F3hvSbtbbU9XhtmY4BcNs+m7GM14x4t13xn421ifTdNims7FZGWKK2fy02g/LJJKOTng8evegD3Mj+Fkyp4I7VI0pOCxyO3Fc/Pe3mheFdONwI76eExW93cTSCNVXHzSknr7Dqa4vUviyDrUNvoWk/bNMMywmeUlJJiSBmNfTnvQB1HiTwTpviPxFDqupyzNFHa/Zvs6EAH5s5J6101nFBY20drZRJb2sI2xxRrhVFLdMI3KspbPUelJ5ioq7ctuwFAPJ9BQA873zGi7pW4Cgc1JNYzWVuJJihBO0Kp6GpvmsB5aAG+lGXcnPljHAFTaqzG0s7eVh5hId/Xgf40AZ6IFUZ649c4r8//Cf/ACNWjf8AX7D/AOhiv0D5IPc+h71+fnhP/katG/6/Yf8A0MUMEHiz/katZ/6/Zv8A0M192eG28zwtphcZ/wBDj9SeBjp+FfCfiz/katZ/6/Zv/QzX3R4NLN4Q0V1B4tlz78mhAzUBJGMAyAgADqfepWWaBQLiMx5Pyk9KSBgt5byMAAHAbNal7IEklW4jeW3dgrIgyRn+IcigDNB+bj60u4ZGMcdvWo545IGaNo5hCf8AVTOF+b24J/XrihH3KMYOOCP60AZA8I+Hnt1hk0m2KB3f7mDliSeevU15T8Qfh/caDM97o4kutIZdx/ieA9wfUe9e4Z7kgH2OaFYbmXAJxkgjgg0AfKIIZQQQR1HHWgdOK9j8efDSO9kk1Lwz5VvcEM0tiflSVvVD/CT6dK4+H4Z+JZtIN6LaCOTG4WckgExH8s+2aBnGHNXdB1O60XWLbULB9s8LdD0dTwyn2IqM6bqAd1On3odDhlMDfKfyqT+yNUBx/Zl9n/rg3+FAHpt18VILa0DaXpEovGxk3EuYl9eByawtQ1vU/iXrWk6OIYLKFHZyYgWVePmdj9Og965mHw5rs5VYdGv2LHAzCR/OvePAfh4+F/B1tb3hiS7YvcXcuRgM3Ozd3CjAoEctrHwosfsJOh306XqjgXJ3JL7cfdNUPDnwplmHn+JJ/KGSBbWzZLD3ft+FdFqfxG02y1SO2t7c3FsOJbp32hevCjq3Irz7WPiF4gurmZ4tQW3hkBCQW4GIhng5Izn3oA9f1XVdI8L6UkV3NDaw20YSK0jILlR0VVryvUvidrdzcs+nJBY2/wDDGyCRv+BE9/pXHT3jXbtNdK01yxy07uS7exzUBHG7PH8qAPV/Anj261XVY9L1pImmnyILmJdmW67WHTnHBr0OC2Z5fLJ/1jYz6eteHfC+1N146004ysG+4b22qcfqRXv2nyeZPI6pyiE49+lABMRJKrAEIo2qv+FJFGChVTu7enFPZcZ3KBjoQPyqT5jhVxgfxDjg0ARMoEi9ULYUd8H1+lJgPEbTP+kIGlj47AjP8/8AOKlxvViQCVPHvRFIYp0xn5SDtI5oAz45lfBZCD14qxE6kquDyehqOWNYrucgE4b5QD260tqNt0hYBVzk5PAHfmgDwDx9r83iLxDcTO/+iW0jW9tH2VVOCfqSK5xyFBLY9ea19f0sadr17FFdQXdkbhpFuLdw42MxPIHcZ6e1QarHa2T3unRJFdBZVaO8BIJTHTHoc0DLvhvS4T4ksrbXSbRJVEkUdwhAuM9EB9D60/Urq5v7L+w7yJ7e50NpZdPC/fRQfmiJ9hyp9qtaf4ivF06HSdTig1CPiW3lumy8QHKhH7AEDin6Lcwar4ivtY1W9soL1Ss4SZiiyfwtjHXjPFAj1n4ca9N4j8H2l7dSebdRM0EzKOSy9/xGDXT7s4OfxNcr8NPDUWh6fqklrdQ3NhfTia2ED7kVMYGfeuseM9j0PoaAGEDBxgGmJEiTPLhtzDH3iQPoKztc8R6L4ej3axqkFvIRuEI+aR/oo5rkNF+KUGv+JbTSNG0G+mSeQK9zIwHlp3cqOg+uKAO61LTbDVLGSy1GzgubWTh0dAR/9Y1l+E/B9l4cSWLS4I0tSSWLku7d+WPQCtvVbqPTIA85aSV28uCFcbpWPRVryz4keLRpl3Gl/dPdamqbV0O0l229uSPvXEg5Y4/hFAGh8Ub7S/EPh5oY7qF7CzuA8szSeXDJIAcIGH3sH0rzXw/4i8O6F4ig1K4tr7UkhX93FDGFjhkPBlUNy2BxXNavqV3q8sUmoTB1iG2GCNQkUI9EQcD69feqWPc0DPqXT9Ttdc0631PTLg3FncDMb9CPVWHYjoRW7otsAXu5kJWDIjX1b1/pXjf7PrzS2PiGyUsYVuIXj9Fdlw2PrgGvd721ZLKC3gfZEn3yOpwP8aBFGOD7ZcMrEruO5j0ZfxqrcT/aL2abjyx8ie4HerMnm2llsd/39x8q+qoOpqgRhcKOBxQA59u0Oxxj9a/P3wn/AMjVo3/X7D/6GK+/JQXk8tME+mOpNfAfhP8A5GrRv+v2H/0MUMEHiz/katZ/6/Zv/QzX3H4Il2eDNDB4/wBGUD8zXw54s/5GrWf+v2b/ANDNfd3gW0+1fDzQ3UDzFtQCAclgCfyNCA0XyYmAwy47nrWjaT/a7XDj9/Cu1/Vl7GsuIbBlVBUHBxRvksrhZ4VzjkjpuHcUAasW1laGaPMEnVOu31IrKntWs7zy85B5R+ziteRYpUE0I3RSD8j6Gpr22jfSxCzLGyLmNn52mgDFQlwNo+YdlrnPEnjXRfD9yba9lluLxcb4YFDFPqegPtXS6acXI3jG/gcE8/hXy/qHnf2le/aixuPPk83d13bjnNAHt1r8TPDNwgLzXcDn+CSAk/mOK6ew1HT7/T49QtbtDZvkiVz5Y469a+ZokVg7ykhEHbqT2FOu7y4u7a2t7iaSS3tlKQxFvljBOSAPqaAPom58YeHLU4n8QWQI7K+/+VY+ofE/w5Zxsba4ub+QfdSGMqGP+82BXgoUdhR1J4oGeoT/ABj1FopVg0i2ikLfu3aZmwPcY5NcJrviHV9elL6tfzzpklYw2I1+ijisrpTgM4wMUAAH1NKOvpQBxzxSjB9aAHAVasblrR5GWOOTzEMbLIMgqevHr71W/wA8Vp6dpz6zcWOnaZbN9vmZg0hfcu3+8R/CBzz3oA9I+DmlRwaXd6wQ/nXDm2QEcLGvJI+p4/CvTrOPyLZ37y4A9gKpabY22j6Pa6dbHMVtGEBx949z+JzV6KRoY0S4XCkfKSMfpQIliR9oYKCQNwBPJNNYBkUbWU5Bye9NWWKNMu+/HRVqNriR1IJ2qecA5oAsr84CAnDcdOB9aaQwPzD1IJFRRXLA7JBuU9CDzUplhCIPOyBkkMDmgBLpFKRTMM7l2Mo7kd65P4kXclp4B1WW2PlyOFiJHZWYA4/Cusln82MQxAsqkt09qyda0pdd8O6hpsjBftMRRHx9xxyp/MCgD5kUCPGwbcdMcVchuopJI0v49yBuZRw5HofUVBdQT2d1NbXcTRXULmOWNuqsKhPoevpQM37PSNU1OdfLt91vAoXz7hhHAiHp854xU8vhmGN2V/EvhtG6hRcFv1ArNurmefwlp1tcXLtawXcvlW5bgAqCWx6ZOKywy7CqooU9cCgD0LwZaQ+HNasr2Tx3pVvZuw863tHaXzl9COg+teuweNPDdxciFNXt45GGVErBQR6g9K+XsAg/KAPpTHVWXDKCO/egD6A8e+BNB8YavFqSa5BZai8awM0UiSLKq9PlJ689qg8J3Hgn4e2+pQ6frcep6xImZU3DfMUBxGuBhe/FeCQqttPFNAFSWJg6MoGVPrWjBG98Li506MrqEANxJDEMmQZyXQeoPUUAXLvxfqd7fDULiSSW/DM8U0r58jOcBF6AgHGa50jLO7lmkdi7uTksx6k+pre8Y6cdPv7ObyZIkv7RLsI4xhiMMB+P86wfegBG47U1iQQEUvIxCIijJZicBR7kmiR1jjLOwCAckmvYfgv4GdJovFOvQlNo3abayLg5/wCezg/+Oj8aAO5+Gnhp/CHhyztp9h1ORvtV2w/56MPu/RRgfhXdR3yvp8016uED7QAPvfSs5myCwPJ5ZqrTyPIY4xu2xjAHYCgQktwbi6aWUAMeAvoPSgP87Jwe5Yf0qKOJnIO35QcEmtG0tVmO9gEt1+857+woAS0QW8X2pwMr8sQ/vN6/hX55eE/+Rq0b/r9h/wDQxX6LzXFu0oeKHzHQALu+6o+lfnR4T/5GrRv+v2H/ANDFAw8Wf8jVrP8A1+zf+hmvuP4cPnwNocsW5ZBBjPcEMa+HPFn/ACNWs/8AX7N/6Ga+3fhnM3/CB6PwFAiK575DHOaBHZAR3LkviC4P8Y+6/wCHaq17bPBgS4Oeh7UpkG1Q3TjkVdt7lJIvJuvmUjCseh9s+tAGbZzNb7iys0DnEienoRV/U4xLFHcoxliAw23n/gWKbNaT27FoMOv909ce/rVaGea2ctbsACfmjI4P4dqAI1UEhkYHHSvKPit4NKXF74ms5Fjs2xJfQ4y0bZAMi+oPcfjXrEgMkkjwDYh5KdhQGRkdbhEZGUq6MuQynjBHcUAfMWp/Y90f9m+cbYDB87G4v3Jx61RPNez618LrT7FrU3h+VhJPbg2tlJyqSq27Ct1APIwa8YbcHeKRHilQ7XjcYZG9CO1Aw6jjFJQx5waQkAeooAUYzxS/pSUfSgB+RSj1JxTPqcD0rZ8N+G9T8R3HlaXbsYwcNcOCIk+p7/QUAUtOs7jUb6CysYzLczNtRB/M+g96978I+HoPDGjrbIySXr/Nc3AHLN/dX0UVP4Q8I6f4Xsitv+/vZFxNdMMM3sB2FbFnBFPcESSbIh0zxu9s0CHWqHBmbBAOFU/xGnX8jSvFGCzuoOTjJ5NSyzJHzFhpegC8qg/xqbToY2t1kEmy4ckFlbBA+lAGO/mCQq5K85wRjirKsDkjkdq2ZLdpl2XCwuR91uQQawrqCWB9qxsW7gc59xQBKzfI3pjio4IpJpTHENzDnj/GpLGCSeXBB3453DGBWxbwPEuyJoo88sUGS350AULHfaztHNujd02qx7elSSo0EjOEKxniQf3G9fpU2qpCtqXZv3y8AE8t7VHa3yhAbnfwMFtuQy+hoA4/x54LsPFUYuvM+yapGoVblRlXHYOO/wBeoryS9+HXimC4EMWni6DHCSwyAofc55Fe8zMoncoMQ7ztBPQVOZ0KhVG1sjGOKAPmjxXYf2RrT6SZFlaxRYpGXp5hAZ8ficfhWRk5r2D4p+ArrUdRl1vQ1Et1Ioa6tARlyBjenvgYI7146+5JmilVopUOGjcFWX6g0DFyTnvSE8n+lBJ5zTTQAmfzH4VLYXtzpuo2uo6fL5V5ayCWJ/cdj6gjg1CevpUecyxxojSTSNtSNF3Mx9AKAPafFRHxX+HlrreiW5j13R5mjnsdwJII+ZVPfPDLXl2l+FPEWr3X2aw0W88wHDNMvlov1Y17b8HPDF74b8M3L6mDBe6jMJ5Ie8KgYVT74613BlIjCoWbnmgR5r4M+E9jos0GoeJZl1O/jO+OzjX9xGw6E/3iPfivTJA0rF7g4GfuigAJk4OfU9TSMC3J5wOAe1AEbMz5CgAZ69qfa2M0pJTcQerdBV2B7GKFC/zS45GMkGorvUPMXamUj9M8mgB2y3gP71vPkH8C8KPqaimmklYbyNq8BV6D6VVaY9c4HamGVj0OB65zQBZZwvO7ivz28J/8jVo3/X7D/wChiv0DhQOQ5xtHQ+pr8/PCf/I1aN/1+w/+hihgg8Wf8jVrP/X7N/6Ga+1/hZIT4B0nceNrAZ+pr4o8Wf8AI1az/wBfs3/oZr62+Eni7RP+EWstK1G+i0/UYmdQLj5Y5MklSrdOlCGenbBt3R8bh65BqNi6LtYcfpSpAWXzIXWZeoaJwyml8wqSrk89sUCJrW+ZV2yL5ka9PUfQ1JdXUd0VKR4I/jcYJ9qqh403MpIUDnrUmdwBzweelACbMkkZDdAexHvSBgThhh+4NOU5BBxu688Us0e5FVhnjIOeaAIsMhYphGHIweKx/Efh3Q/EOW1ixX7VjaLmM7JB/wACHX8a1gxjbZIfl7NU0gVo41VcjGSM5FAHk+pfCEMzPpGs/KeRHcx5x7bl/wAKxpfhTr658qfT5cf9NCuf0r2kwjqo2j2NKVf+GTp/eoA8MHwx8Sk/6uzH/bccj16VdtfhRrMjD7VfWFunc5ZyP0r2ULKx5cAe1BQupDOcHvjrQBwmk/DTQbBUa/kuNUmHJDHZH/3yOtdtaL9niSK0ijigQYWNBtVR7AVOiAD5QMj0pyjAxknn060ANfL/AHmGDTXQeWA7ZA9qlKA4Dg4HOKYwyPmz19aAI0I2YXbk8BR1+tSrEACOSfWkRYxyobJ60/aMnlgfrQBYjuZowquPNQDOG649jVmS5ZVV4hviYYVsZIPoaoAgEknI7CrVrG0MAlt5thlPzKy5XPSgCRrl0Xdcnap4WMD5m9/YVTkuZpOAxRP7q/402ZJBcP5p3Sjgt/hTCgJOe1ADWCk4Y5bv60ybcUAU/J0zU2wAdB64xQVBOCuQRg+1ACoFCbRz9RTDEuPlLDPfrTlTaAoOAOvGak2kEEEHtQBAVcN8rBvTPWs/VdC07W42XVtMtrk/32XDj/gQ5rVchM7iP60iyqw+83ryMUAed3Xwl0CSUtDc6laA/wAIcSKD7Zqqfg5pbHK63qAGeRsTkV6mg4AGcEc5NGBnowHtQB5pF8IfDkZzcXmpS46nzdo/Suo8PeENC8OzGbRtPRZyMGeQ73H4npXQ4HJ2/maaWjyecnrxzQAuWbBkIb8cAUMwXLE/TFMEu5vkAHPengqCSWJPYmgAQE5Zxg9AKk7c5x+dM8xOuS3bNJ5xOfLXP1oAkMaEYYEj6YqmVHmNtHy1I5kZfmfH0p0cLu4jjUsxoAYVHljoBz1pAB1Xkj0HWszVvE3h/R52t9S1i3jnTl0jO4r9cfSs1/iL4JTldeWd+0cCln/LFAHT8hflyo9fSvz98J/8jVo3/X7D/wChivrjVvi9DEsi+HtGycfLNeN1/wCAivkfwn/yNWjf9fsP/oYoGHiz/katZ/6/Zv8A0M1pxeNdQjthAbaxkjHZ0Y/+zV9G6t/yFb3/AK7P/wChGqlIDwrTfiXr2lyb9OMFs2d37vzAPy34rsLX9orxjDarDPa6NdsvSWeCTePxWQV6LRQB53/w0V4txj+z9C/78Tf/AB2lH7Rfi4EEWGhjGePJmx/6Nr0OigDz8ftH+Lx/zDtB/wC/Ev8A8dob9o/xcwH/ABLdBBHcQzf/AB2vQKKAPO2/aK8WsQTp+hf9+Jf/AI7R/wANE+LRnbYaGB6CGb/47XolFAHnq/tG+LVGP7O0E+5gm/8AjtB/aM8W5z/Z2g/9+Jv/AI7XoVFAHnv/AA0Z4uzn+z9C/wC/E3/x2l/4aN8Xf9A7Qf8AvxN/8dr0GigDz7/ho3xd/wBA7Qf+/E3/AMdoH7R3i8DH9n6EfrBL/wDHa9BooA8+/wCGjfF3/QO0H/vxN/8AHaP+GjfF+MDT9CH/AGwm/wDjteg0UAeff8NHeLv+gdoP/fib/wCO0f8ADRvi7/oHaCf+2E3/AMdr0GigDz8ftH+LgcjTdA/78Tf/AB2pYP2lfGUIYJp2gEE5INvMef8Av7Xd0UAefyftH+L3dnbTtBLMcn9xN/8AHaP+GjvF2c/2doP/AH4m/wDjtegUUAefL+0d4uHTTtB/78Tf/HaU/tHeLic/2boH/fib/wCO16BRQB5+f2jvFx/5hugf9+Jv/jtA/aO8Xf8AQO0H/vxN/wDHa9AooA89H7Rvi8ZxYaFk9/Il/wDjtNH7RXi4dLDQx/2xl/8AjteiUUAed/8ADRXi8AgWOiAf9cZv/jtIP2ifFo6WGh5658mb/wCO16LRQB54f2ivFp66foR/7Yzf/HaQftE+LB/zDtB/78Tf/Ha9EooA87H7RXi3/oHaD/34m/8AjtKP2ivFoA/4l2hcf9MJv/jteh0UAeej9ozxaP8AmG6B/wB+Jv8A47S/8NHeL+2naCP+2E3/AMdr0GigDz7/AIaO8XHrpugf9+Jv/jtRaj+0T4wvNLnso7XRrQTDa01vDKJMegJkOPyr0aigDwF/HmpOCGtbDnqfLbJ9z81Qr4zv1leRbezDPwfkbp6fer6EooA8Abx1qbNloLMjGMbGA/RqyfCf/I1aN/1+w/8AoYr6Vq3pP/IVsv8Arsn/AKEKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sarcoidosis with marked scarring and parenchymal distortion in the upper lobes, bulla formation, and cavities. These changes are irreversible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22128=[""].join("\n");
var outline_f21_39_22128=null;
var title_f21_39_22129="Tobramycin: Pediatric drug information";
var content_f21_39_22129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tobramycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/59/35762?source=see_link\">",
"       Tobramycin (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/54/15209?source=see_link\">",
"       Tobramycin (systemic therapy and oral inhalation): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12845 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22129=[""].join("\n");
var outline_f21_39_22129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/59/35762?source=related_link\">",
"      Tobramycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/54/15209?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_39_22130="Patient information: Abdominal aortic aneurysm (The Basics)";
var content_f21_39_22130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15324\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/4/44098\">",
"         Abdominal aortic aneurysm anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/0/33797\">",
"          Abdominal aortic aneurysm repair",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30307\">",
"         Patient information: Aortic dissection (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/62/34787\">",
"         Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Abdominal aortic aneurysm (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/abdominal-aortic-aneurysm-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H20386055\">",
"      <span class=\"h1\">",
"       What is an abdominal aortic aneurysm?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An &ldquo;abdominal aortic aneurysm&rdquo; is a problem in the aorta, the main blood vessel that comes out of the heart. Blood flows through the aorta to the rest of the body. The &ldquo;abdominal aorta&rdquo; is the part of the aorta that goes from the heart, down through the belly, and then branches to supply blood to the legs. In people with an abdominal aortic aneurysm, also known as an &ldquo;AAA,&rdquo; a part of the abdominal aorta balloons out or bulges (",
"      <a class=\"graphic graphic_figure graphicRef52216 \" href=\"UTD.htm?43/4/44098\">",
"       figure 1",
"      </a>",
"      ). If the bulge bursts, the condition becomes very dangerous. A burst aorta causes lots of internal bleeding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386062\">",
"      <span class=\"h1\">",
"       What are the symptoms of an AAA?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with abdominal aortic aneurysms have no symptoms. When symptoms do occur, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain in the belly or back",
"       </li>",
"       <li>",
"        A small lump in the upper part of the belly that pulses, meaning it swells and shrinks in rhythm with the heartbeat (doctors notice this more often than patients do)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Abdominal aortic aneurysms can burst with no warning. Doctors suggest you get tested if there is a high risk that you might have the condition. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386069\">",
"      <span class=\"h1\">",
"       Who is most likely to get an AAA?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your risks go up if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Are a man",
"       </li>",
"       <li>",
"        Are older than 60 (with every year of life after that, your risk goes up even more)",
"       </li>",
"       <li>",
"        Smoke",
"       </li>",
"       <li>",
"        Are white",
"       </li>",
"       <li>",
"        Have family members who have had the condition",
"       </li>",
"       <li>",
"        Have heart disease or other conditions that affect the blood vessels",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386076\">",
"      <span class=\"h1\">",
"       Can AAAs be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But you can greatly reduce your risk by not smoking. If you have high blood pressure, it is also important to control your blood pressure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386083\">",
"      <span class=\"h1\">",
"       Is there a test for AAAs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The most common test is called &ldquo;abdominal ultrasonography.&rdquo; For this test, your doctor will wave a wand over your belly. The wand uses sound waves to make a picture of your aorta. The picture can show if you have an aneurysm or some other problem. Your doctor might also want to press on your belly to feel for anything unusual.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386090\">",
"      <span class=\"h1\">",
"       How are AAAs treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on how big the aneurysm is. Some people need surgery to repair the aneurysm. Others do not.",
"     </p>",
"     <p>",
"      You might not need to have your aneurysm repaired right away if your aneurysm is smaller than 4 centimeters (1.6 inches) wide or if it is growing slowly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386097\">",
"      <span class=\"h1\">",
"       What should I do if I have an AAA but don&rsquo;t need surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will suggest that you",
"      <strong>",
"       :",
"      </strong>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get tested every 6 months to 3 years, depending on how big your aneurysm is, to see how fast your aneurysm is growing",
"       </li>",
"       <li>",
"        Take a beta-blocker &ndash; This is a medicine that slows the growth of abdominal aortic aneurysms.",
"       </li>",
"       <li>",
"        Call your doctor if you start having pain in your belly or back. Pain can be a sign that the aneurysm is bursting.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386104\">",
"      <span class=\"h1\">",
"       When should AAAs be repaired?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Repair is the best treatment if your aneurysm is at risk of bursting. Here are some signs that yours might burst:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        It is bigger than 5.5 centimeters (2.2 inches) wide",
"       </li>",
"       <li>",
"        It grows more than 0.5 centimeters (0.2 inches) in 6 months",
"       </li>",
"       <li>",
"        You have other conditions that affect your blood vessels",
"       </li>",
"       <li>",
"        Your aneurysm is more than twice as big as your aorta should be",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386111\">",
"      <span class=\"h1\">",
"       How are AAAs repaired?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Aneurysms can be fixed in one of two ways (",
"      <a class=\"graphic graphic_figure graphicRef57520 \" href=\"UTD.htm?33/0/33797\">",
"       figure 2",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Traditional &ldquo;open&rdquo; surgery &ndash; For open surgery, the doctor cuts open your belly and replaces the bulging part of the aorta with a tube called a &ldquo;graft.&rdquo; This tube is made from manmade materials. It is sewn into place. Blood can flow normally through it.",
"       </li>",
"       <li>",
"        Endovascular stent graft &ndash; To repair the aorta with an endovascular stent graft, the doctor cuts into a blood vessel in your thigh (at the spot where your thigh meets the rest of your body) and inserts a folded graft. Then the doctor threads the graft up to the bulging part of the aorta and unfolds it. This type of graft is not sewn into place. Blood flows through the graft.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386118\">",
"      <span class=\"h1\">",
"       What should I know about the two repair options?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Open surgery is a little riskier in the short term. But it fixes the problem for good. Endovascular repair is less risky in the short term. But it needs to be carefully followed. That&rsquo;s because endovascular grafts sometimes slip out of place and need to be fixed. (Fixing them usually involves a simpler procedure than the first one.) If your doctor offers you a choice between the two options, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the risks of each procedure for me?",
"       </li>",
"       <li>",
"        What kind of follow up will I need with each option?",
"       </li>",
"       <li>",
"        What is likely to happen if I do not have either treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20386272\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/38/30307?source=see_link\">",
"       Patient information: Aortic dissection (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=see_link\">",
"       Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/39/22130?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15324 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22130=[""].join("\n");
var outline_f21_39_22130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386055\">",
"      What is an abdominal aortic aneurysm?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386062\">",
"      What are the symptoms of an AAA?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386069\">",
"      Who is most likely to get an AAA?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386076\">",
"      Can AAAs be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386083\">",
"      Is there a test for AAAs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386090\">",
"      How are AAAs treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386097\">",
"      What should I do if I have an AAA but don&rsquo;t need surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386104\">",
"      When should AAAs be repaired?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386111\">",
"      How are AAAs repaired?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386118\">",
"      What should I know about the two repair options?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20386272\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15324\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/4/44098\">",
"      Abdominal aortic aneurysm anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/0/33797\">",
"       Abdominal aortic aneurysm repair",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/38/30307?source=related_link\">",
"      Patient information: Aortic dissection (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_39_22131="Perioral dermatitis";
var content_f21_39_22131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perioral dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple acneiform papules can be seen on this young woman. Note the characteristic sparing around the lips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22131=[""].join("\n");
var outline_f21_39_22131=null;
var title_f21_39_22132="Prurigo of pregnancy";
var content_f21_39_22132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prurigo of pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Miriam Kelt Pomeranz, MD. Department of Dermatology. New York University School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22132=[""].join("\n");
var outline_f21_39_22132=null;
var title_f21_39_22133="Palmoplantar pustulosis old lesions";
var content_f21_39_22133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palmoplantar pustulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In palmoplantar pustulosis, pustules become old over several days, become brown in color and dry, and desquamate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22133=[""].join("\n");
var outline_f21_39_22133=null;
var title_f21_39_22134="Clorazepate: Pediatric drug information";
var content_f21_39_22134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clorazepate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=see_link\">",
"    see \"Clorazepate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/9/7317?source=see_link\">",
"    see \"Clorazepate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tranxene&reg; T-Tab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clorazepate&reg;;",
"     </li>",
"     <li>",
"      Novo-Clopate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=see_link\">",
"      see \"Clorazepate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anticonvulsant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Initial dose: 0.3 mg/kg/day; maintenance dose: 0.5-3 mg/kg/day divided 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 9-12 years: Initial: 3.75-7.5 mg/dose twice daily; increase dose by 3.75 mg at weekly intervals, not to exceed 60 mg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: Initial: Up to 7.5 mg/dose 2-3 times/day; increase dose by 7.5 mg at weekly intervals; usual dose: 0.5-1 mg/kg/day; not to exceed 90 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anxiety: Adults: 7.5-15 mg 2-4 times/day; usual daily dose: 30 mg/day in divided doses; range: 15-60 mg/day; may be given as single dose of 15 mg at bedtime, with subsequent dosage adjustments based on patient response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alcohol withdrawal: Adults: Initial: 30 mg, then 15 mg 2-4 times/day on first day; maximum daily dose: 90 mg; gradually decrease dose over subsequent days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dipotassium: 3.75 mg, 7.5 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tranxene&reg; T-Tab&reg;: 3.75 mg, 7.5 mg, 15 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F153745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10380945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM217562.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM217562.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food or water to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unstable in water. Store at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from moisture; keep bottle tightly closed; dispense in tightly closed, light-resistant container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct anticonvulsant in the management of partial seizures (FDA approved in ages &ge;9 years and adults); treatment of anxiety disorders (FDA approved in adults); management of alcohol withdrawal (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Clorazepate may be confused with clofibrate, clonazepam, KlonoPIN&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F153750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, irritability, lightheadedness, memory impairment, nervousness, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased/decreased, constipation, diarrhea, nausea, salivation decreased, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice, transaminase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clorazepate dipotassium or any component; cross-sensitivity with other benzodiazepines may exist; narrow-angle glaucoma; avoid using in patients with pre-existing CNS depression or severe uncontrolled pain",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal disease. Clorazepate may cause CNS depression which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive medication (effects with other sedative drugs or ethanol may be potentiated) and in patients with depression.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Physical and psychological dependence may occur; abrupt discontinuation may cause withdrawal symptoms or seizures; use with caution in patients with a psychological predisposition for drug dependence. Clorazepate is not recommended for use in depressive neuroses or psychotic reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify heathcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA is requiring that a Medication Guide be developed for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F153739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7793123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nordiazepam, the active metabolite of clorazepate, crosses the placenta and is measurable in cord blood and amniotic fluid. Teratogenic effects have been observed with some benzodiazepines (including clorazepate); however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to clorazepate during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excessive CNS depression, respiratory rate, and cardiovascular status; with prolonged use: CBC, liver enzymes, renal function; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1051840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 0.12-1 mcg/mL (SI: 0.36-3.01 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the gamma-aminobutyric acid (GABA) receptor complex and modulating GABA, which is a major inhibitory neurotransmitter in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Nordiazepam: 97% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly decarboxylated to desmethyldiazepam (nordiazepam; primary metabolite; active) in acidic stomach prior to absorption; hepatically to oxazepam (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nordiazepam: 40-50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxazepam: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in urine (62% to 67% of dose); feces (15% to 19%); found in urine as conjugated oxazepam (3-hydroxynordiazepam) (major urinary metabolite) and  conjugated p-hydroxynordiazepam and nordiazepam (smaller amounts)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/9/7317?source=see_link\">",
"      see \"Clorazepate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use (withdrawal symptoms or an increase in seizure activity may occur). May cause dry mouth. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. Report persistent CNS effects (eg, confusion, depression, headache, dizziness, fatigue, changes in cognition); muscle tremor; visual disturbances; worsening of seizure activity, or loss of seizure control.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Fenichel GM,",
"      <i>",
"       Clinical Pediatric Neurology: A Signs and Symptoms Approach",
"      </i>",
"      , 2nd ed, Philadelphia, PA: WB Saunders Co, 1993.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fujii T, Okuno T, Go T, et al, &ldquo;Clorazepate Therapy for Intractable Epilepsy,&rdquo;",
"      <i>",
"       Brain Dev",
"      </i>",
"      , 1987, 9(3):288-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22134/abstract-text/2889387/pubmed\" id=\"2889387\" target=\"_blank\">",
"        2889387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mimaki T, Tagawa T, Ono J, et al, &ldquo;Antiepileptic Effect and Serum Levels of Clorazepate on Children With Refractory Seizures,&rdquo;",
"      <i>",
"       Brain Dev",
"      </i>",
"      , 1984, 6(6):539-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22134/abstract-text/6152517/pubmed\" id=\"6152517\" target=\"_blank\">",
"        6152517",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13172 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22134=[""].join("\n");
var outline_f21_39_22134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153709\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153710\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051836\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051829\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153686\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153671\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153745\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10380945\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051842\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051832\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051841\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153752\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153750\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051845\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051828\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051827\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153739\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153680\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7793123\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051835\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051840\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051826\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051844\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051834\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13172|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=related_link\">",
"      Clorazepate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/9/7317?source=related_link\">",
"      Clorazepate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_39_22135="Eyelid anatomy";
var content_f21_39_22135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Oblique section through the upper and lower eyelids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 555px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Smith's Ophthalmic Plastic and Reconstructive Surgery, 2nd ed, Mosby, St. Louis 1998. Copyright &copy; 1998 Frank A Nesi, MD and Richard D Lisman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22135=[""].join("\n");
var outline_f21_39_22135=null;
var title_f21_39_22136="Dasatinib: Drug information";
var content_f21_39_22136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dasatinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/9/44181?source=see_link\">",
"    see \"Dasatinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3020472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sprycel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sprycel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3020476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3020532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The effect of discontinuation after complete cytogenetic remission is achieved has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic myelogenous leukemia (CML), Philadelphia chromosome-positive (Ph+), newly diagnosed in chronic phase:",
"     </b>",
"     Oral: 100 mg once daily until disease progression or unacceptable toxicity. In clinical studies, a dose escalation to 140 mg once daily was allowed in patients not achieving hematologic or cytogenetic response at recommended initial dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CML, Ph+, resistant or intolerant:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic phase:",
"     </i>",
"     100 mg once daily until disease progression or unacceptable toxicity. In clinical studies, a dose escalation to 140 mg once daily was allowed in patients not achieving hematologic or cytogenetic response at recommended initial dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Accelerated or blast phase:",
"     </i>",
"     140 mg once daily until disease progression or unacceptable toxicity. In clinical studies, a dose escalation to 180 mg once daily was allowed in patients not achieving hematologic or cytogenetic response at recommended initial dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL), Ph+:",
"     </b>",
"     Oral: 140 mg once daily until disease progression or unacceptable toxicity. In clinical studies, a dose escalation to 180 mg once daily was allowed in patients not achieving hematologic or cytogenetic response at recommended initial dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors:",
"     </b>",
"     Avoid concomitant administration with strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, ketoconazole, nefazodone, protease inhibitors, telithromycin, voriconazole, grapefruit juice); if concomitant administration with a strong CYP3A4 inhibitor cannot be avoided, consider reducing dasatinib from 100 mg once daily to 20 mg once daily",
"     <b>",
"      or",
"     </b>",
"     from 140 mg once daily to 40 mg once daily, with careful monitoring. If reduced dose is not tolerated, the strong CYP3A4 inhibitor must be discontinued or dasatinib therapy temporarily held until concomitant inhibitor use has ceased. When a strong CYP3A4 inhibitor is discontinued, allow a washout period (~1 week) prior to adjusting dasatinib dose upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inducers:",
"     </b>",
"     Avoid concomitant administration with strong CYP3A4 inducers (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, St John&rsquo;s wort); if concomitant administration with a strong CYP3A4 inducer cannot be avoided, consider increasing the dasatinib dose with careful monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3020533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15121210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling. However, &lt;4% of dasatinib and metabolites are renally excreted.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7882679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3020534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Chronic phase CML",
"     </i>",
"     (100 mg daily starting dose): For ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , withhold treatment until ANC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; then resume treatment at the original starting dose if recovery occurs in &le;7 days. If platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or recurrence of ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;7 days, withhold treatment until ANC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; then resume treatment at 80 mg once daily (second episode). For third episode, further reduce dose to 50 mg once daily (for newly-diagnosed patients) or discontinue (for patients resistant or intolerant to prior therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Accelerated or blast phase CML and Ph+ ALL",
"     </i>",
"     (140 mg once daily starting dose): For ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , if cytopenia unrelated to leukemia, withhold treatment until ANC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; then resume treatment at the original starting dose. If cytopenia recurs, withhold treatment until ANC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; then resume treatment at 100 mg once daily (second episode) or 80 mg once daily (third episode). For cytopenias related to leukemia (confirm with marrow aspirate or biopsy), consider dose escalation to 180 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Nonhematologic toxicity:",
"     </b>",
"     Withhold treatment until toxicity improvement or resolution; if appropriate, resume treatment at a reduced dose based on the event severity. Fluid retention is managed with diuretics and supportive care. Effusions may require diuretics and/or dose interruption. Corticosteroids (eg, prednisone 20 mg/day for 3 days) may be considered for pleural or pericardial effusion with significant symptoms (hold dasatinib and reinitiate at a decreased dose when effusion resolves). Rash may be managed with steroids (topical or systemic), treatment interruption, dose reduction, or discontinuation (NCCN CML guidelines v.2.2013). Discontinue with confirmed pulmonary arterial hypertension.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3020543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sprycel&reg;: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3020474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3020536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer once daily (morning or evening). May be taken without regard to food. Swallow whole; do not break, crush, or chew tablets. Take with a meal or with a large glass of water if GI upset occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3020479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of chronic myelogenous leukemia (CML) in chronic, accelerated or blast (myeloid or lymphoid) phase resistant or intolerant to prior therapy (including imatinib); treatment of newly-diagnosed Philadelphia chromosome-positive (Ph+) CML in chronic phase; treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to prior therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7882583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Post-stem cell transplant (allogeneic) follow-up treatment of CML; treatment of gastrointestinal stromal tumor (GIST)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dasatinib may be confused with bosutinib, imatinib, nilotinib, ponatinib, SUNItinib, vandetanib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3020508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Fluid retention (21% to 35%; grades 3/4: 1% to 8%), superficial edema (3% to 19%; grades 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (12% to 33%), fatigue (8% to 24%), fever (5% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (11% to 21%; includes drug eruption, erythema, erythema multiforme, erythematous rash, erythrosis, exfoliative rash, follicular rash, heat rash, macular rash, maculopapular rash, milia, papular rash, pruritic rash, pustular rash, skin exfoliation, skin irritation, urticaria vesiculosa, vesicular rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (grades 3/4: 5% to 18%), hypokalemia (grades 3/4: &le;15%), hypocalcemia (grades 3/4: &lt;1% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (18% to 31%; grades 3/4: &le;5%), nausea (9% to 24%), vomiting (5% to 16%), abdominal pain (3% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (grades 3/4: 19% to 85%), neutropenia (grades 3/4: 22% to 79%),  anemia (grades 3/4: 11% to 74%), hemorrhage (6% to 26%; grades 3/4: 1% to 9%), neutropenic fever (grades 3/4: 1% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (&le;19%), myalgia (3% to 13%), arthralgia (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pleural effusion (12% to 24%; grades 3/4: &le;11%), dyspnea (3% to 20%; grades 3/4: 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (9% to 12%, includes bacterial, fungal, viral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to &lt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Generalized edema (&le;1%), pericardial effusion (&le;3%; grades 3/4: &le;1%), CHF/cardiac dysfunction (&le;4%; includes cardiac failure, cardiomyopathy, diastolic dysfunction, ejection fraction decreased, left ventricular dysfunction, ventricular failure); arrhythmia, chest pain, flushing, hypertension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: CNS bleeding (&le;3%; grades 3/4: &le;3%), chills, depression, dizziness, insomnia, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, dermatitis, dry skin, eczema, hyperhydrosis, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal bleeding (2% to 9%; grades 3/4: 1% to 7%), abdominal distention, anorexia, colitis (including neutropenic colitis), constipation, dyspepsia, enterocolitis, gastritis, mucositis/stomatitis, oral soft tissue disorder, taste alteration, weight loss/gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Contusion, pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (grades 3/4: &le;6%), ALT increased (grades 3/4: &le;5%), AST increased (grades 3/4: &le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle inflammation (4%), muscle weakness, neuropathy, peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disorder (blurred vision, acuity reduced, visual disturbance), xerophthalmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (grades 3/4: &le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary edema (&le;4%; grades 3/4: &le;3%), cough, lung infiltration, pneumonia (bacterial, viral or fungal), pneumonitis, pulmonary hypertension, upper respiratory tract infection/inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Herpes virus infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute coronary syndrome, acute febrile neutrophilic dermatosis, acute respiratory distress syndrome, amnesia, anal fissure, angina, anxiety, ascites, asthma, atrial fibrillation, atrial flutter, bronchospasm, bullous conditions, cardiomegaly, cerebrovascular accident, cholecystitis, cholestasis, conjunctivitis, cor pulmonale, creatine phosphokinase increased, deep vein thrombosis (DVT), dysphagia, embolism, erythema nodosum, esophagitis, gynecomastia, hand-foot syndrome (palmar-plantar erythrodysesthesia syndrome), hematoma, hematuria, hepatitis, hypersensitivity, hyperuricemia, hypoalbuminemia, hypotension, interstitial lung disease, libido decreased, livedo reticularis, malaise, menstrual irregularities, MI, myocarditis, neutropenic colitis, optic neuritis, pancreatitis, panniculitis, pericarditis, petechiae, photosensitivity, pigmentation disorder, platelet aggregation abnormal, polyuria, proteinuria, pulmonary arterial hypertension, pulmonary embolism, pure red cell aplasia, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, renal failure, rhabdomyolysis, seizure, sepsis, skin ulcer, syncope, temperature intolerance, tendonitis, thrombophlebitis, thrombosis, TIA, tremor, tumor lysis syndrome, upper gastrointestinal ulcer, ventricular arrhythmia, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3020503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to dasatinib or any other component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3020504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Severe dose-related bone marrow suppression (thrombocytopenia, neutropenia, anemia) is associated with treatment; dosage adjustment or temporary interruption may be required for severe myelosuppression; the incidence of myelosuppression is higher in patients with advanced CML and Ph+ ALL. Monitor blood counts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular adverse events: Cardiomyopathy, diastolic dysfunction, heart failure (congestive), left ventricular dysfunction, and MI have been reported. Monitor for signs and symptoms of cardiac dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention: Fluid retention, including pleural and pericardial effusions, severe ascites, severe pulmonary edema, and generalized edema were reported; may be dose-related. A chest x-ray is recommended for symptoms suggestive of effusion (dyspnea or dry cough). Utilizing once-daily dosing is associated with a decreased frequency of fluid retention. The risk for pleural effusion is increased in patients with hypertension, prior cardiac history and a twice a day administration schedule; interrupt treatment for grade &ge;2 effusion; may consider reinitiating at a reduced dose after resolution (Quint&aacute;s-Cardama, 2007). Use with caution in patients where fluid accumulation may be poorly tolerated, such as in cardiovascular disease (HF or hypertension) and pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Fatal intracranial hemorrhage has been reported in association with dasatinib use; severe hemorrhage (including CNS, GI) may occur due to thrombocytopenia. In addition to thrombocytopenia, dasatinib may also cause platelet dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary arterial hypertension (PAH): Has been reported with use, sometimes after &gt;12 months of therapy. Evaluate for underlying cardiopulmonary disease prior to therapy initiation and during therapy; evaluate and rule out alternative etiologies in patients with symptoms suggestive of PAH (eg, dyspnea, fatigue) and interrupt therapy if symptoms are severe. Discontinue permanently with confirmed PAH diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: May prolong QT interval; use caution in patients at risk for QT prolongation, including patients with long QT syndrome; patients taking antiarrhythmic medications or other medications that lead to QT prolongation or potassium-wasting diuretics; patients with cumulative high-dose anthracycline therapy, and conditions which cause hypokalemia or hypomagnesemia. Correct hypokalemia and hypomagnesemia prior to initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment due to extensive hepatic metabolism; patients with ALT or AST &gt;2.5 times the upper limit of normal (ULN) or total bilirubin &gt;2 times the ULN were excluded from clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants or antiplatelets: Use with caution in patients taking anticoagulants or medications interfering with platelet function; not studied in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inducers/inhibitors: Avoid concomitant use with CYP3A4 inducers and inhibitors; if concomitant use cannot be avoided, consider dasatinib dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Elderly may be more likely to experience dyspnea and fluid retention; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3020515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3020514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Dasatinib may enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Dasatinib may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Dasatinib. Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: Dasatinib may increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Dasatinib. Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Dasatinib. Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Dasatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3020518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Dasatinib serum concentrations may be increased when taken with grapefruit or grapefruit juice. Management: Avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may increase metabolism and decrease dasatinib plasma concentration).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3020480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5520659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have demonstrated fetal abnormalities (skeletal malformations, reduced ossification, edema, microhepatia) and fetal death. May cause fetal harm if administered to a pregnant woman. Not recommended for use during pregnancy or if contemplating pregnancy. Effective contraception is recommended for men and women of childbearing potential. Pregnant women are advised to avoid contact with crushed or broken tablets.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3020502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6743584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue dasatinib or to discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3020535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May be taken without regard to food. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sprycel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $5301.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $10602.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70 mg (60): $10602.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $10298.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $10298.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     140 mg (30): $10298.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3020538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     CBC with differential (weekly for 2 months, then monthly or as clinically necessary); bone marrow biopsy; liver function tests, electrolytes including calcium, phosphorus, magnesium; monitor for fluid retention; ECG monitoring if at risk for QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation; chest x-ray is recommended for symptoms suggestive of pleural effusion (eg, cough, dyspnea)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Thyroid function testing recommendations (Hamnvik, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Without pre-existing thyroid hormone replacement: TSH at baseline, then monthly for 4 months, then every 2-3 months",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Sprycel (AR, AT, AU, BE, BG, BR, CH, CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IN, IT, KP, MT, MY, NL, NO, NZ, PE, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3020521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     BCR-ABL tyrosine kinase inhibitor; targets most imatinib-resistant BCR-ABL mutations (except the T315I and F317V mutants) by distinctly binding to active and inactive ABL-kinase. Kinase inhibition halts proliferation of leukemia cells. Also inhibits SRC family (including SRC, LKC, YES, FYN); c-KIT, EPHA2 and platelet derived growth factor receptor (PDGFR&beta;)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3020523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 2505 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Dasatinib: 96%; metabolite (active): 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (extensive); metabolized by CYP3A4 (primarily), flavin-containing mono-oxygenase-3 (FOM-3) and uridine diphosphate-glucuronosyltransferase (UGT) to an active metabolite and other inactive metabolites (the active metabolite plays only a minor role in the pharmacology of dasatinib)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~85%, 19% as unchanged drug); urine (~4%, 0.1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Apperley JF, Cortes JE, Kim DW, et al, &ldquo;Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(21):3472-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/19487385/pubmed\" id=\"19487385\" target=\"_blank\">",
"        19487385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Assouline S, Laneuville P and Gambacorti-Passerini C, &ldquo;Panniculitis During Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(24):2623-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/16775249/pubmed\" id=\"16775249\" target=\"_blank\">",
"        16775249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berveiller P, Andreoli A, Mir O, et al, &ldquo;A Dramatic Fetal Outcome Following Transplacental Transfer of Dasatinib,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2012, 23(7):754-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/22421368/pubmed\" id=\"22421368\" target=\"_blank\">",
"        22421368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradeen HA, Eide CA, O'Hare T, et al, &ldquo;Comparison of Imatinib, Dasatinib (BMS-354825), and Nilotinib (AMN107) in an N-Ethyl-N-Nitrosourea (ENU)-Based Mutagenesis Screen: High Efficacy of Drug Combinations,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 108(7):2332-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/16772610/pubmed\" id=\"16772610\" target=\"_blank\">",
"        16772610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Copland M, Hamilton A, Elrick LJ, et al, &ldquo;Dasatinib (BMS-354825) Targets an Earlier Progenitor Population Than Imatinib in Primary CML But Does Not Eliminate the Quiescent Fraction,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(11):4532-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/16469872/pubmed\" id=\"16469872\" target=\"_blank\">",
"        16469872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cornelison M, Jabbour EJ, and Welch MA, &ldquo;Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients With Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner,&rdquo;",
"      <i>",
"       J Support Oncol",
"      </i>",
"      , 2012, 10(1):14-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/22244674/pubmed\" id=\"22244674\" target=\"_blank\">",
"        22244674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortes J, Rousselot P, Kim DW, et al, &ldquo;Dasatinib Induces Complete Hematologic and Cytogenetic Responses in Patients With Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(8):3207-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/17185463/pubmed\" id=\"17185463\" target=\"_blank\">",
"        17185463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guilhot F, Apperley J, Kim DW, et al, &ldquo;Dasatinib Induces Significant Hematologic and Cytogenetic Responses in Patients With Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia in Accelerated Phase,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(10):4143-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/17264298/pubmed\" id=\"17264298\" target=\"_blank\">",
"        17264298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochhaus A, Kantarjian HM, Baccarani M, et al, &ldquo;Dasatinib Induces Notable Hematologic and Cytogenetic Responses in Chronic-Phase Chronic Myeloid Leukemia After Failure of Imatinib Therapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(6):2303-09.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/17138817/pubmed\" id=\"17138817\" target=\"_blank\">",
"        17138817",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Cortes J, Kim DW, et al, \"Phase 3 Study of Dasatinib 140 mg Once Daily versus 70 mg Twice Daily in Patients With Chronic Myeloid Leukemia in Accelerated Phase Resistant or Intolerant to Imatinib: 15-Month Median Follow-up,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(25):6322-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/19369231/pubmed\" id=\"19369231\" target=\"_blank\">",
"        19369231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, Shah NP, Cortes JE, et al, &ldquo;Dasatinib or Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: 2-year Follow-up From a Randomized Phase 3 Trial (DASISION),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(5):1123-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/22160483/pubmed\" id=\"22160483\" target=\"_blank\">",
"        22160483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Shah NP, Hochhaus A, et al, &ldquo;Dasatinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(24):2260-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/20525995/pubmed\" id=\"20525995\" target=\"_blank\">",
"        20525995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lilly MB, Ottmann OG, Shah NP, et al, &ldquo;Dasatinib 140 mg Once Daily versus 70 mg Twice Daily in Patients With Ph-Positive Acute Lymphoblastic Leukemia Who Failed Imatinib: Results From a Phase 3 Study,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2010, 85(3):164-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/20131302/pubmed\" id=\"20131302\" target=\"_blank\">",
"        20131302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montemurro M, Domont J, Blesius A, et al, &ldquo;Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors: A Multicenter Phase II Trial of the SAKK (SAKK 56/07),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(15s):10033 [abstract 10033 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN) &ldquo;Practice Guidelines in Oncology&trade;: Chronic Myelogenous Leukemia Version 2.2013.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/cml.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottmann O, Dombret H, Martinelli G, et al, &ldquo;Dasatinib Induces Rapid Hematologic and Cytogenetic Responses in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Intolerance to Imatinib: Interim Results of a Phase 2 Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(7):2309-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/17496201/pubmed\" id=\"17496201\" target=\"_blank\">",
"        17496201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quintas-Cardama A, Han X, Kantarjian H, et al, &ldquo;Dasatinib-Induced Platelet Dysfunction,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      2007, 110:2941 [abstract 2941 from 2007 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, O'brien S, et al, &ldquo;Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(25):3908-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/17761974/pubmed\" id=\"17761974\" target=\"_blank\">",
"        17761974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saglio G, Hochhaus A, Goh YT, et al, \"Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-up in a Phase 3 Study: Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2010, 116(16):3852-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/20564086/pubmed\" id=\"20564086\" target=\"_blank\">",
"        20564086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shah NP, Kantarjian HM, Kim DW, et al, &ldquo;Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(19):3204-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/18541900/pubmed\" id=\"18541900\" target=\"_blank\">",
"        18541900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shah NP, Kim DW, Kantarjian H, et al, &ldquo;Potent, Transient Inhibition of BCR-ABL With Dasatinib 100 mg Daily Achieves Rapid and Durable Cytogenetic Responses and High Transformation-Free Survival Rates in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance, Suboptimal Response or Intolerance to Imatinib,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2010, 95(2):232-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/20139391/pubmed\" id=\"20139391\" target=\"_blank\">",
"        20139391",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talpaz M, Shah NP, Kantarjian H, et al, &ldquo;Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(24):2531-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/39/22136/abstract-text/16775234/pubmed\" id=\"16775234\" target=\"_blank\">",
"        16775234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trent JC, Wathen J, von Mehren M, et al, &ldquo;A Phase II Study of Dasatinib for Patients With Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15s):10006 [abstract 10006 from 2011 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8852 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22136=[""].join("\n");
var outline_f21_39_22136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020472\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663157\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020476\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020532\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020533\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15121210\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7882679\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020534\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020543\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020474\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020536\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020479\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7882583\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401602\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020508\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020503\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020504\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020515\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020514\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020518\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020480\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5520659\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020502\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743584\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020535\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322945\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020538\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539976\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020521\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020523\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8852\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8852|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/9/44181?source=related_link\">",
"      Dasatinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_39_22137="Toxoplasmosis and pregnancy";
var content_f21_39_22137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxoplasmosis and pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/39/22137/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/39/22137/contributors\">",
"     Ruth Gilbert, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/39/22137/contributors\">",
"     Eskild Petersen, MD, DMSc, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/39/22137/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/39/22137/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/39/22137/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/39/22137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/39/22137/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/39/22137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma gondii is a ubiquitous protozoan parasite that infects humans in various settings. The parasite is mainly acquired during childhood and adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/1\">",
"     1",
"    </a>",
"    ]. In industrially developed, temperate climate countries, the prevalence of infection has declined over the last 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/1\">",
"     1",
"    </a>",
"    ], with 10 to 50 percent of adults aged 15 to 45 years displaying serological evidence of past infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/2\">",
"     2",
"    </a>",
"    ]. Much higher rates of infection (up to 80 percent) are found in the tropics in communities exposed to contaminated soil, undercooked meat, or unfiltered water [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once a person is infected, the parasite lies dormant in neural and muscle tissue and will never be eliminated. Studies based in Europe and North America suggest that the large majority of immune competent humans are able to limit the spread of the parasite and the associated tissue damage, ensuring that it remains in its dormant form [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3\">",
"     3",
"    </a>",
"    ]. Inflammation of the retina and choroid (retinochoroiditis) is the most frequent, permanent manifestation of toxoplasmic infection. In Europe and North America, up to 1 percent of infected individuals eventually develop such lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence has been accumulating over the last 15 years that these findings are not applicable to parts of Latin America, where clinical manifestations of infection are much more common and more severe, probably because of the predominance of more diverse and more virulent parasite genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A comparison of European and Brazilian cohort studies of newborns identified by universal screening showed that eye lesions were larger and more numerous and more likely to impair vision in Brazilian cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to Europe and North America, acquisition of toxoplasmosis during childhood or adulthood in Brazil accounts for high levels of eye disease. In parts of Brazil, up to 20 percent of the population has toxoplasmic retinochoroiditis, resulting in high levels of visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Toxoplasmosis is a leading cause of blindness in South America [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/17\">",
"     17",
"    </a>",
"    ], but not in Europe or North America [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A detailed discussion of toxoplasmosis in nonpregnant individuals can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When toxoplasmic infection is acquired for the first time during pregnancy, infection can be transmitted to the fetus, resulting in congenital toxoplasmosis and associated neurological and ocular manifestations. In this topic, we will focus on primary maternal infection and its effect on the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma gondii is an obligate intracellular parasite that exists in three forms: the oocyst, which is shed only in cat feces; the tachyzoite (a rapidly dividing form observed in the acute phase of infection); and the bradyzoite (a slow growing form observed within tissue cysts) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3\">",
"     3",
"    </a>",
"    ]. During a primary infection, a cat can shed millions of oocysts daily from its alimentary canal for a period of one to three weeks. These oocysts become infective one to five days later and may remain infectious for over a year, especially in warm, humid environments. Cats typically develop immunity after a primary infection; therefore, recurrent infection with passage of oocysts is unlikely.",
"   </p>",
"   <p>",
"    In developed temperate climate countries, the main source of maternal infection is thought to be ingestion of bradyzoites contained in undercooked or cured meat or meat products. Ingestion of oocysts, from contact with soil or water, or eating soil-contaminated fruit or vegetables is also a major source of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3-5,20-24\">",
"     3-5,20-24",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal toxoplasmosis infection is acquired orally. Fetal infection results from transmission of parasites via the placenta following primary maternal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3\">",
"     3",
"    </a>",
"    ]. It is likely that transmission occurs in most cases during the parasitemic phase in the days after infection and before the development of a serologic response. To survive and multiply, the tachyzoite invades host cells, especially in the brain and muscle, where it forms tissue cysts which can remain dormant for years. In immune competent animal models, tissue cysts can be formed within a week of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. It is not known how long this process takes in the relatively immunologically immature fetus. The transition from acute infective tachyzoite form, which is responsible for cell damage, to the dormant bradyzoite form contained in tissue cysts impenetrable to antibiotics, has important implications for the therapeutic \"window of opportunity.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MATERNAL INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of maternal infection during pregnancy ranges from 1 to 8 per 1000 susceptible pregnancies, with the highest reported rates in France [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/27\">",
"     27",
"    </a>",
"    ]. The risk of transmitting infection to the fetus increases steeply with the gestational age at seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunocompetent women infected prior to conception virtually never transmit toxoplasmosis to the fetus, although rare exceptions have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/29-35\">",
"     29-35",
"    </a>",
"    ]. Immunocompromised women (eg, women with AIDS or taking immunosuppressive medications) may have parasitemia during pregnancy despite preconceptional infection; their infants are at risk of congenital infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital toxoplasmosis secondary to reinfection is a rare event; this phenomenon has been reported in approximately six women over the past three decades [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/37\">",
"     37",
"    </a>",
"    ]. One well-documented case demonstrated that prior immunity to toxoplasma did not protect against reinfection with an atypical strain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infection in the mother is usually asymptomatic. When symptoms of infection occur, they are nonspecific, such as fatigue, fever, headache, malaise, and myalgia. Lymphadenopathy is a more specific sign of the disease. In a prospective European cohort study, lymphadenopathy was noted in 7 percent of 1144 infected pregnant women before diagnosis of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link&amp;anchor=H5#H5\">",
"     \"Toxoplasmosis in immunocompetent hosts\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women who experience a mononucleosis-like illness (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link&amp;anchor=H5#H5\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    ), but who have a negative heterophile test, should be tested for toxoplasmosis as part of their diagnostic evaluation. We do not recommend routinely screening for toxoplasmosis in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal infection during pregnancy is most accurately diagnosed when based on a minimum of two blood samples at least two weeks apart showing seroconversion from negative to positive toxoplasma-specific IgM or IgG.",
"   </p>",
"   <p>",
"    Such serial testing of susceptible women is usually feasible only as part of a prenatal screening program. Monthly or three monthly retesting schedules operate in parts of Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/38\">",
"     38",
"    </a>",
"    ]: the more frequently a woman is retested, the greater the chance of detecting infection early on, and when treatment is more likely to be effective. However, the costs of frequent testing and the chances of false positive results increase as the frequency of retesting increases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/27,39\">",
"     27,39",
"    </a>",
"    ]. Thus, women may undergo invasive prenatal investigations and be treated unnecessarily. These potential harms have to be weighed against potential benefits of treatment, which have been found only for rare, serious neurological sequelae of congenital toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Randomized controlled trials are needed to determine if these benefits outweigh the harms of screening.",
"   </p>",
"   <p>",
"    In the United States, clinicians are usually faced with the need to interpret a positive IgM or IgA or low IgG avidity test result from a single sample. None of these tests reliably predict recent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/38,42,43\">",
"     38,42,43",
"    </a>",
"    ]. Although the IgM response lasts a median of 10 to 13 months, depending on the type of test used, there is substantial variation in duration between individuals, and about one-quarter of infected women have a persistent IgM response lasting years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/43\">",
"     43",
"    </a>",
"    ]. For women whose first prenatal test at 13 weeks of gestation was IgM and IgG positive, the probability that their infection occurred after conception is 1 to 3 percent, depending on the test used [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/43\">",
"     43",
"    </a>",
"    ]. A low IgG avidity can also persist for years in some women [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usefulness of a rising IgG titer has never been adequately evaluated and is subject to error because of lack of reproducibility in many laboratories when specimens are analyzed on different days. However, the combination of a positive IgM and negative IgG result, with both tests becoming positive two weeks later, thereby ruling out a nonspecific IgM response, is evidence of infection occurring about two weeks before the first positive IgM result [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In the United States, serological diagnosis of acute infection should be confirmed by a reference laboratory, such as the Palo Alto Medical Foundation Research Institute's Toxoplasma Serology Laboratory (650-853-4828).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FETAL INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of fetal infection increases with advancing gestational age at the time of maternal seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/28\">",
"     28",
"    </a>",
"    ]. A meta-analysis of all available cohorts estimated the risk of transmission to be 15 percent when the mother seroconverted at 13 weeks, 44 percent at 26 weeks, and 71 percent at 36 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/28\">",
"     28",
"    </a>",
"    ]. Although these figures are based on women who were mostly treated during pregnancy, they are likely to be generalizable to untreated women, as there is no clear evidence that prenatal treatment administered in screening programs reduces the risk of mother to child transmission of toxoplasmosis (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Rationale for prenatal treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fetal sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal ultrasound can be useful to provide diagnostic information, although findings are nonspecific. The most common intracranial sonographic findings in fetal toxoplasmosis are intracranial hyperechogenic foci or calcifications and ventricular dilatation, which are poor prognostic signs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/40,48-50\">",
"     40,48-50",
"    </a>",
"    ]. Cerebral ventricular dilatation is generally bilateral and symmetrical. In one series of 32 proven infected cases, evolution was always very rapid over a period of a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/48\">",
"     48",
"    </a>",
"    ]. In a European prospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/51\">",
"     51",
"    </a>",
"    ], abnormal sonographic findings of intracranial calcification or ventricular dilatation were found in 7 percent",
"    <span class=\"nowrap\">",
"     (14/218)",
"    </span>",
"    of infected fetuses; however, as reported in other studies, such lesions appear only after 21 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/40,48\">",
"     40,48",
"    </a>",
"    ]. Abnormal findings involving areas other than the brain (eg, ascites) are less specific for toxoplasmosis. Intrahepatic densities, increased thickness and hyperdensity of the placenta, ascites, and rarely pericardial and pleural effusions have also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/48\">",
"     48",
"    </a>",
"    ]. Serial ultrasound is useful if late termination is being actively considered.",
"   </p>",
"   <p>",
"    Intrauterine growth restriction and microcephaly are not characteristic of congenital toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/48,52\">",
"     48,52",
"    </a>",
"    ]. Stillbirth appears to be a rare complication; a prospective European cohort study of 1208 infected women found the risk of stillbirth among 448 women infected during the first trimester was no higher than that in the general obstetrical population matched for age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/52\">",
"     52",
"    </a>",
"    ]. An observed association between early maternal infection and preterm delivery may be due to obstetric intervention, rather than the disease itself [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main purpose of prenatal diagnosis of fetal infection is to help decide whether to change prenatal treatment from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    -sulfonamide combination (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Rationale for prenatal treatment'",
"    </a>",
"    below). As prenatal diagnosis requires amniocentesis, which is an invasive test with a small but well-established risk of miscarriage, clinicians need to ensure that women are sufficiently informed to enable them to weigh the potential benefits and risks when deciding whether to undergo prenatal diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .) Although there have been no randomized controlled trials comparing types of treatment, none of the comparative cohort studies have provided any evidence that a pyrimethamine-sulphonamide combination is more effective than spiramycin for any outcomes related to congenital toxoplasmosis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/4,28\">",
"     4,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some women, prenatal diagnosis is important to aid in their decision as to whether to terminate the pregnancy. Exclusion of fetal infection by prenatal diagnosis can also prevent unnecessary postnatal treatment in children without clinical signs of toxoplasmosis and at low risk of congenital infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/40,51\">",
"     40,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) for T. gondii DNA in amniotic fluid is the best method for diagnosing fetal infection, but accuracy varies among laboratories and techniques and sensitivity is lower in early than in late pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/42,51,53\">",
"     42,51,53",
"    </a>",
"    ]. Real time PCR appears to be more sensitive than conventional PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. The sensitivity of real time PCR testing was illustrated by a prospective French study of real time PCR for T. gondii that reported sensitivity and specificity of 92.2 and 100 percent, respectively; sensitivity was not affected by gestational age at the time of maternal seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/57\">",
"     57",
"    </a>",
"    ]. Four of the 51 infected children had negative amniotic fluid PCR results; maternal seroconversion occurred at 13, 20, 28, and 32 weeks of gestation in these cases.",
"   </p>",
"   <p>",
"    The four false negative tests were performed five to nine weeks after maternal seroconversion, thus timing of amniocentesis was unlikely to be a factor. Furthermore, at least one study has reported no association between a positive amniocentesis and time since seroconversion, thereby challenging the rationale for past recommendations that amniocentesis be delayed until four weeks after seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mouse inoculation of amniotic fluid, used in some European centers to diagnose fetal infection, is hard to justify, given the high cost, limited sensitivity, and the fact that results take four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/51\">",
"     51",
"    </a>",
"    ]. Cordocentesis has not been widely used for more than a decade because of the risk of fetal loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians recommend fetal ultrasound to detect fetal abnormalities suggestive of infection in women with negative amniotic fluid testing, in case of a false negative PCR result [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/58\">",
"     58",
"    </a>",
"    ]. However, this strategy subjects a very large number of uninfected fetuses to unnecessary repeated ultrasounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RATIONALE FOR PRENATAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to management of toxoplasmosis during pregnancy was largely based upon the experience of Desmonts and Couvreur, who reported nearly 40 years ago that prenatal treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    was associated with a reduced risk of congenital infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/59\">",
"     59",
"    </a>",
"    ]. Their findings were flawed because they did not take into account the fact that the treated women in their study seroconverted in early pregnancy, and, therefore, were at low risk of fetal infection, whereas the untreated women mostly seroconverted in late pregnancy and were at high risk of fetal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/60\">",
"     60",
"    </a>",
"    ]. Their findings have since been refuted by a series of cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/28,38,61,62\">",
"     28,38,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether any treatment reduces the risk of mother to child transmission remains controversial, as no randomized controlled trials evaluating this issue have been performed. The most robust evidence comes from a systematic review and individual patient data meta-analysis of 20 European cohort studies (1438 women) in which universal screening for toxoplasmosis in pregnancy was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/28\">",
"     28",
"    </a>",
"    ]. The analysis assessed the effect of timing and type of prenatal treatment on mother-to-child transmission of infection and clinical manifestations before age 1 year. Prenatal treatment consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    alone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    -sulphonamides and spiramycin followed by pyrimethamine-sulphonamides.",
"   </p>",
"   <p>",
"    The authors found weak evidence that treatment started within three weeks of seroconversion reduced mother-to-child transmission compared with treatment started after eight or more weeks (OR 0.48, 95% CI 0.28-0.80; p = 0.05), but they could not distinguish whether this was a real benefit of treatment or a bias due to late detection and inclusion in the cohort of women at increased risk of fetal infection. Only one in five women were treated within three weeks of seroconversion, despite the fact that most (76 percent) were identified in France, where a regimen of monthly retesting is mandated by law. Thus, even if early treatment is effective, it will be difficult to identify and treat women so quickly after seroconversion.",
"   </p>",
"   <p>",
"    In addition, the authors found no statistically significant evidence that early treatment reduced the risk of intracranial lesions detected after birth, or of retinochoroiditis detected during infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/28\">",
"     28",
"    </a>",
"    ]. Two other large cohort studies also found no evidence that prenatal treatment reduced the risk of retinochoroiditis up to school age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. However, there is clear evidence of a reduction in serious neurological sequelae or postnatal death in children with congenital toxoplasmosis whose mothers were treated during pregnancy. In a European study involving 293 infected fetuses, 8 percent had serious neurological sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/40\">",
"     40",
"    </a>",
"    ]. The authors estimated that prenatal treatment reduced the risk of serious neurological sequelae or death by three-quarters. They also estimated that, to prevent one case of serious neurological sequelae or death after maternal infection at 10 weeks of pregnancy, it would be necessary to treat three fetuses with confirmed infection. To prevent one case of serious neurological sequelae or death after maternal infection at 30 weeks of pregnancy, 18 fetuses would need to be treated.",
"   </p>",
"   <p>",
"    There is fairly strong evidence, again from cohort studies, that treatment with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    -sulfonamide combination is no more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    alone for reducing the risk of clinical manifestations in the infected infant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/28,40,61,63,65\">",
"     28,40,61,63,65",
"    </a>",
"    ]. Nevertheless, pyrimethamine-sulfonamide combinations are widely recommended, based on evidence that levels of spiramycin in fetal blood samples are about half those found in maternal serum, and may be insufficient for treating fetal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3,66\">",
"     3,66",
"    </a>",
"    ]. However, this issue remains controversial, given the difficulty in measuring blood levels of spiramycin and the extent of variation in blood levels between women [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    -sulfonamide combinations are more effective than other drugs is important and undermines the rationale for prenatal diagnosis. Clinicians and women need to be aware that we simply do not know whether changing treatment from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    to a pyrimethamine-sulphonamide combination if the fetus is infected is beneficial.",
"   </p>",
"   <p>",
"    Adverse drug effects are more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    -sulfonamide combinations than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    . A European multicenter cohort study found adverse effects requiring treatment cessation in 3.4 percent",
"    <span class=\"nowrap\">",
"     (11/322)",
"    </span>",
"    of women prescribed pyrimethamine-sulfonamide compared with 1.7 percent",
"    <span class=\"nowrap\">",
"     (13/780)",
"    </span>",
"    of women prescribed spiramycin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/38\">",
"     38",
"    </a>",
"    ]. A prospective study of 48 children with congenital toxoplasmosis identified by neonatal screening found that 7 experienced adverse reactions leading to treatment cessation; 6 of the 7 patients with adverse reactions had neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, there is evidence that prenatal treatment reduces serious neurological sequelae of congenital toxoplasmosis, but no evidence of any effect on ocular disease, vision, or mother-to-child transmission of infection. Randomized controlled trials are required to determine whether the benefits of prenatal treatment justify the potential harms and costs of prenatal screening. However, if toxoplasmosis is identified through testing because of maternal symptoms or a high risk of exposure to infection, then treatment is justified, though uncertainty remains about the type of treatment and duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of evidence of treatment efficacy, prenatal treatment is usually offered to pregnant women who are diagnosed with toxoplasmosis. The uncertainty about treatment effectiveness, risk of adverse effects, and the high probability that the child will not be impaired should be discussed with women when deciding whether or not to treat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Spiramycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women who become infected during pregnancy are generally treated immediately with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    (1 g orally every eight hours without food), which is a macrolide antibiotic similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . It is concentrated in the placenta, where it is thought to treat placental infection and thus helps to prevent transmission to the fetus, at least theoretically [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3,69\">",
"     3,69",
"    </a>",
"    ]. The drug is licensed in Europe and Canada, and is available in the United States for use in pregnancy from Rhone-Poulenc (Montreal, Quebec) if an Investigational New Drug (IND) number is obtained from the Food and Drug Administration (FDA) (\"compassionate use\" pathway).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pyrimethamine and sulfadiazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    is a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    antagonist which can cause dose-related bone marrow suppression with resultant anemia, leukopenia, and thrombocytopenia. It is teratogenic in animals when given in large doses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     Sulfadiazine",
"    </a>",
"    , another folic acid antagonist, works synergistically with pyrimethamine against T. gondii tachyzoites, and can also cause bone marrow suppression and reversible acute renal failure. Due to the potential toxicity of these drugs, their use during pregnancy should only be considered if fetal infection has been documented, although there is no clinical evidence that these drugs are more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3,28,61,63,65\">",
"     3,28,61,63,65",
"    </a>",
"    ]. There are no direct maternal benefits from these drugs.",
"   </p>",
"   <p>",
"    Various dosing regimens have been proposed, but even in France, where prenatal screening has operated for 30 years, treatment regimens vary [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3,38,70\">",
"     3,38,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A three-week course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      (50 mg once per day orally or 25 mg twice per day) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      orally divided into two to three doses), alternating with a three-week course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"       spiramycin",
"      </a>",
"      (1 g orally three times per day) until delivery.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      (25 mg once per day orally) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      (4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      orally divided into two to four doses) administered continuously until term.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      calcium (folinic acid, 10 to 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      orally) is added during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      administration to prevent bone marrow suppression. Monitoring of complete blood counts and platelet counts should be performed weekly, and treatment discontinued, if a significantly abnormal result is reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    has been used successfully to treat T. gondii in both an animal model and in humans with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3,55,56,71\">",
"     3,55,56,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .) It is a Category B drug that has been used safely for treatment of Chlamydia trachomatis infections in pregnancy. Large clinical trials are necessary to determine whether this agent, or perhaps",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , is an effective alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    to prevent in utero infection with T. gondii [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    (100 mg loading dose orally followed by 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    combined with azithromycin (500 mg per day) has been found to have equivalent effects to the combination with sulfonamide in a randomized controlled trial of adult patients with toxoplasmic retinochoroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/72\">",
"     72",
"    </a>",
"    ]. Women intolerant of pyrimethamine may consider",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/73\">",
"     73",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. However, the safety and efficacy of these drugs for treating in-utero toxoplasmosis infection are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TERMINATION OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of women have their pregnancies terminated because of toxoplasmosis. Within the prenatal screening program in France, termination is discouraged unless there is definite evidence of fetal infection based on PCR performed in a reference laboratory and evidence of intracranial abnormalities on fetal ultrasound. The rationale for this approach is that most infected babies have a good prognosis and, on average, do not differ in their development at three to four years from uninfected children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/70,76,77\">",
"     70,76,77",
"    </a>",
"    ]. However, fetuses with ultrasound evidence of intracranial lesions are thought to be at high risk of serious neurological sequelae or postnatal death. It is not clear whether prenatal treatment reduces these risks once intracranial lesions are apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/40\">",
"     40",
"    </a>",
"    ]. In France, approximately 1.4 percent",
"    <span class=\"nowrap\">",
"     (17/1208)",
"    </span>",
"    of infected women undergo termination and just over half of these pregnancies have proven fetal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/38,51\">",
"     38,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546172\">",
"    <span class=\"h1\">",
"     NEONATAL MANAGEMENT AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma infection in the newborn is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link\">",
"     \"Congenital toxoplasmosis: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7672?source=see_link\">",
"     \"Congenital toxoplasmosis: Treatment, outcome, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of primary infection is based upon avoidance of sources of infection. While access to reliable information on sources of infection is undoubtedly important, a systematic review found a lack of clear evidence that such information changes women's behavior during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/78\">",
"     78",
"    </a>",
"    ]. Evidence from case control studies of risk factors in Europe has identified the following principal sources of infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Travel to less developed countries is a major risk factor, especially to South America, where more virulent parasite genotypes predominate [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/5,20\">",
"       5,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women should avoid drinking unfiltered water in any setting [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/4,5,79\">",
"       4,5,79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Avoid ingesting soil by observing strict hand hygiene after touching soil. Fruit and vegetables should be washed before eating [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/20,22\">",
"       20,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Raw or undercooked meat is an important source of infection. Cutting boards, knives, and the sink and counters should be washed after food preparation. Avoid mucous membrane contact when handling uncooked meat. Women should also avoid tasting meat while cooking [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/4,5,20,22\">",
"       4,5,20,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Meat should be cooked to 152&ordm;F (66&ordm;C) or higher, or frozen for 24 hours in a household freezer (at less than -12&ordm;C), both of which are lethal to tachyzoites and bradyzoites [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/80\">",
"       80",
"      </a>",
"      ]. Meat farmed in strict indoor conditions is less likely to be contaminated than outdoor reared meat [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/5\">",
"       5",
"      </a>",
"      ]. There is weak evidence that meat that has been smoked or cured in brine is not safe. The risk of infection is likely to be increased when cured products involve meat from more than one animal and limited drying and curing, as in some local production methods [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/5,21,81\">",
"       5,21,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is some evidence that shellfish can be infected with toxoplasma cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Owning a cat is only weakly associated with acute infection. This is probably because cats only excrete oocysts for three weeks of their life, and people are just as likely to be exposed to oocysts excreted by someone else's cat. Nevertheless, it seems sensible for pregnant women with cats to ask someone else to change the litter box daily (fresh cat feces are not infectious) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/39/22137/abstract/5,20,22\">",
"       5,20,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hand washing is the single most important measure to reduce transmission of microorganisms from one site to another on the same patient. Thus, handwashing is important after activities such as preparing food or gardening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=see_link\">",
"       \"Patient information: Avoiding infections in pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=see_link\">",
"       \"Patient information: Avoiding infections in pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main sources of maternal toxoplasmosis infection are ingestion of contaminated undercooked or cured meat or meat products, soil-contaminated fruit or vegetables, or contaminated unfiltered water. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sources of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal toxoplasmosis infection is usually asymptomatic, but may be manifested by nonspecific symptoms. In most cases, the most serious consequence of maternal infection is transmission to the fetus. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of vertical transmission increases with increasing gestational age at maternal infection. Conversely, the risks of intracranial lesions and serious neurodevelopmental sequelae decrease with increasing gestational age at maternal infection. Rarely, fetal infection leads to stillbirth or neonatal death. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fetal sequelae'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal infection during pregnancy is most accurately diagnosed when based on a minimum of two blood samples at least two weeks apart showing seroconversion from negative to positive toxoplasma-specific IgM or IgG. Polymerase chain reaction (PCR) for T. gondii DNA in amniotic fluid is the best method for diagnosing fetal infection, but is not sensitive when women seroconvert in the first trimester. Sonography of an infected fetus may show intracranial calcification or ventricular dilatation after 21 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not performing routine universal prenatal screening for toxoplasmosis in pregnancy, given there is insufficient evidence that the benefits of prenatal treatment outweigh the potential harms and costs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, testing may be clinically indicated to diagnose infection in women with symptoms of toxoplasmosis or at high risk of recent exposure. In such cases, prenatal treatment is justified to reduce the risk of serious neurological sequelae or postnatal death, although information on the low risk of serious adverse outcome and the risk of adverse drug effects should be shared with women when deciding whether or not to treat. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Rationale for prenatal treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection acquired during pregnancy in South America carries a much higher risk of serious sequelae for the fetus than does infection acquired in Europe or North America. Although evidence is lacking for the effectiveness of treatment for these more virulent strains, we suggest treating women who are tested for clinical indications and acquired infection in South America (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Rationale for prenatal treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women planning pregnancy or who are pregnant, we recommend avoidance of risky behaviors, such as eating raw or undercooked meat or drinking unfiltered water (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Public health interventions include provision of clean filtered water and promoting greater awareness of the sources of infection. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the lack of evidence of cost effectiveness, prenatal treatment is usually offered to pregnant women who are diagnosed with toxoplasmosis. For women with proven fetal infection who choose to be treated,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      is more widely used than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"       spiramycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/1\">",
"      Welton, NJ, Ades, AE. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence. JRSS (C) Applied Statistics 2005; 54:385.",
"     </a>",
"    </li>",
"    <li>",
"     Gilbert RE. Congenital toxoplasmosis: Scientific background, clinical management and control. In: Epidemiology of infection in pregnant women, 1st ed, Petersen E, Amboise-Thomas P (Eds), Springer-Verlag, Paris 2000.",
"    </li>",
"    <li>",
"     Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Infectious Disease of the Fetus adn Newborn Infant, 6th ed, Remington JS, Klein J, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.947.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/4\">",
"      Bahia-Oliveira LM, Jones JL, Azevedo-Silva J, et al. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis 2003; 9:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/5\">",
"      Cook AJ, Gilbert RE, Buffolano W, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. BMJ 2000; 321:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/6\">",
"      Burnett AJ, Shortt SG, Isaac-Renton J, et al. Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology 1998; 105:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/7\">",
"      Perkins ES. Ocular toxoplasmosis. Br J Ophthalmol 1973; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/8\">",
"      Gilbert RE, Stanford MR. Is ocular toxoplasmosis caused by prenatal or postnatal infection? Br J Ophthalmol 2000; 84:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/9\">",
"      Gilbert RE, Dunn DT, Lightman S, et al. Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiol Infect 1999; 123:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/10\">",
"      Wendte JM, Miller MA, Lambourn DM, et al. Self-mating in the definitive host potentiates clonal outbreaks of the apicomplexan parasites Sarcocystis neurona and Toxoplasma gondii. PLoS Genet 2010; 6:e1001261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/11\">",
"      Fraz&atilde;o-Teixeira E, Sundar N, Dubey JP, et al. Multi-locus DNA sequencing of Toxoplasma gondii isolated from Brazilian pigs identifies genetically divergent strains. Vet Parasitol 2011; 175:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/12\">",
"      Gilbert RE, Freeman K, Lago EG, et al. Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis 2008; 2:e277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/13\">",
"      Silveira C, Belfort R Jr, Muccioli C, et al. A follow-up study of Toxoplasma gondii infection in southern Brazil. Am J Ophthalmol 2001; 131:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/14\">",
"      Glasner PD, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol 1992; 114:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/15\">",
"      Portela RW, Bethony J, Costa MI, et al. A multihousehold study reveals a positive correlation between age, severity of ocular toxoplasmosis, and levels of glycoinositolphospholipid-specific immunoglobulin A. J Infect Dis 2004; 190:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/16\">",
"      de Amorim Garcia CA, Or&eacute;fice F, de Oliveira Lyra C, et al. Socioeconomic conditions as determining factors in the prevalence of systemic and ocular toxoplasmosis in Northeastern Brazil. Ophthalmic Epidemiol 2004; 11:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/17\">",
"      de Carvalho KM, Minguini N, Moreira Filho DC, Kara-Jos&eacute; N. Characteristics of a pediatric low-vision population. J Pediatr Ophthalmol Strabismus 1998; 35:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/18\">",
"      de Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/19\">",
"      Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996; 80:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/20\">",
"      Kapperud G, Jenum PA, Stray-Pedersen B, et al. Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway. Am J Epidemiol 1996; 144:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/21\">",
"      Buffolano W, Gilbert RE, Holland FJ, et al. Risk factors for recent toxoplasma infection in pregnant women in Naples. Epidemiol Infect 1996; 116:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/22\">",
"      Baril L, Ancelle T, Goulet V, et al. Risk factors for Toxoplasma infection in pregnancy: a case-control study in France. Scand J Infect Dis 1999; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/23\">",
"      de Moura L, Bahia-Oliveira LM, Wada MY, et al. Waterborne toxoplasmosis, Brazil, from field to gene. Emerg Infect Dis 2006; 12:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/24\">",
"      Boyer K, Hill D, Mui E, et al. Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis 2011; 53:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/25\">",
"      Denkers EY, Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998; 11:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/26\">",
"      L&uuml;der CG, Gross U. Toxoplasmosis: from clinics to basic science. Parasitol Today 1998; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/27\">",
"      Gilbert RE, Peckham CS. Congenital toxoplasmosis in the United Kingdom: to screen or not to screen? J Med Screen 2002; 9:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/28\">",
"      SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thi&eacute;baut R, Leproust S, et al. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007; 369:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/29\">",
"      Gavinet MF, Robert F, Firtion G, et al. Congenital toxoplasmosis due to maternal reinfection during pregnancy. J Clin Microbiol 1997; 35:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/30\">",
"      Hennequin C, Dureau P, N'Guyen L, et al. Congenital toxoplasmosis acquired from an immune woman. Pediatr Infect Dis J 1997; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/31\">",
"      Vogel N, Kirisits M, Michael E, et al. Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis 1996; 23:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/32\">",
"      Boumahni B, Randrianivo H, Flodrops H, et al. [Maternal toxoplasmosis before conception and chorioretinitis in twin sisters]. J Gynecol Obstet Biol Reprod (Paris) 2004; 33:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/33\">",
"      Chemla C, Villena I, Aubert D, et al. Preconception seroconversion and maternal seronegativity at delivery do not rule out the risk of congenital toxoplasmosis. Clin Diagn Lab Immunol 2002; 9:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/34\">",
"      Villena I, Chemla C, Quereux C, et al. Prenatal diagnosis of congenital toxoplasmosis transmitted by an immunocompetent woman infected before conception. Reims Toxoplasmosis Group. Prenat Diagn 1998; 18:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/35\">",
"      Pons JC, Sigrand C, Grangeot-Keros L, et al. [Congenital toxoplasmosis: transmission to the fetus of a pre-pregnancy maternal infection]. Presse Med 1995; 24:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/36\">",
"      Desmonts G, Couvreur J, Thulliez P. [Congenital toxoplasmosis. 5 cases of mother-to-child transmission of pre-pregnancy infection]. Presse Med 1990; 19:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/37\">",
"      Elbez-Rubinstein A, Ajzenberg D, Dard&eacute; ML, et al. Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review. J Infect Dis 2009; 199:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/38\">",
"      Gilbert R, Gras L, European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 2003; 110:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/39\">",
"      Binquet C, Wallon M, Quantin C, et al. [Evaluation of prevention strategies for congenital toxoplasmosis: a critical review of medico-economic studies]. Rev Epidemiol Sante Publique 2002; 50:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/40\">",
"      Cortina-Borja M, Tan HK, Wallon M, et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med 2010; 7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/41\">",
"      McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis 2006; 42:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/42\">",
"      Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 2008; 47:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/43\">",
"      Gras L, Gilbert RE, Wallon M, et al. Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect 2004; 132:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/44\">",
"      Lefevre-Pettazzoni M, Le Cam S, Wallon M, Peyron F. Delayed maturation of immunoglobulin G avidity: implication for the diagnosis of toxoplasmosis in pregnant women. Eur J Clin Microbiol Infect Dis 2006; 25:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/45\">",
"      Meroni V, Genco F, Tinelli C, et al. Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies. Clin Vaccine Immunol 2009; 16:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/46\">",
"      Gras, L, Wallon, M, Pollak, A, Cortina-Borja, M, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centers. Acta Paediatrica Scandinavia 2005; 94:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/47\">",
"      Dunn D, Wallon M, Peyron F, et al. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999; 353:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/48\">",
"      Hohlfeld P, MacAleese J, Capella-Pavlovski M, et al. Fetal toxoplasmosis: ultrasonographic signs. Ultrasound Obstet Gynecol 1991; 1:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/49\">",
"      Malinger G, Werner H, Rodriguez Leonel JC, et al. Prenatal brain imaging in congenital toxoplasmosis. Prenat Diagn 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/50\">",
"      Becker LE. Infections of the developing brain. AJNR Am J Neuroradiol 1992; 13:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/51\">",
"      Thalib L, Gras L, Romand S, et al. Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. BJOG 2005; 112:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/52\">",
"      Freeman K, Oakley L, Pollak A, et al. Association between congenital toxoplasmosis and preterm birth, low birthweight and small for gestational age birth. BJOG 2005; 112:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/53\">",
"      Foulon W, Pinon JM, Stray-Pedersen B, et al. Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. Am J Obstet Gynecol 1999; 181:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/54\">",
"      Romand S, Chosson M, Franck J, et al. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am J Obstet Gynecol 2004; 190:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/55\">",
"      Brenier-Pinchart MP, Morand-Bui V, Fricker-Hidalgo H, et al. Adapting a conventional PCR assay for Toxoplasma gondii detection to real-time quantitative PCR including a competitive internal control. Parasite 2007; 14:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/56\">",
"      Bretagne S, Costa JM. Towards a nucleic acid-based diagnosis in clinical parasitology and mycology. Clin Chim Acta 2006; 363:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/57\">",
"      Wallon M, Franck J, Thulliez P, et al. Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid. Obstet Gynecol 2010; 115:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/58\">",
"      Gay-Andrieu F, Marty P, Pialat J, et al. Fetal toxoplasmosis and negative amniocentesis: necessity of an ultrasound follow-up. Prenat Diagn 2003; 23:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/59\">",
"      Desmonts G, Couvreur J. Congenital toxoplasmosis. A prospective study of 378 pregnancies. N Engl J Med 1974; 290:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/60\">",
"      Thi&eacute;baut R, Leroy V, Alioum A, et al. Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 2006; 124:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/61\">",
"      Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999; 180:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/62\">",
"      Gilbert RE, Gras L, Wallon M, et al. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 2001; 30:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/63\">",
"      Freeman K, Tan HK, Prusa A, et al. Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics 2008; 121:e1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/64\">",
"      Binquet C, Wallon M, Quantin C, et al. Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect 2003; 131:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/65\">",
"      Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 2001; 30:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/66\">",
"      Forestier F, Daffos F, Rainaut M, et al. [Fetomaternal therapeutic follow-up of spiramycin during pregnancy]. Arch Fr Pediatr 1987; 44:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/67\">",
"      Gratzl R, Sodeck G, Platzer P, et al. Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. Eur J Clin Microbiol Infect Dis 2002; 21:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/68\">",
"      Schmidt DR, Hogh B, Andersen O, et al. Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur J Pediatr 2006; 165:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/69\">",
"      Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. J Antimicrob Chemother 1988; 22 Suppl B:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/70\">",
"      Binquet C, Wallon M, Metral P, et al. [Toxoplasmosis seroconversion in pregnant women. The differing attitudes in France]. Presse Med 2004; 33:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/71\">",
"      Godofsky EW. Treatment of presumed cerebral toxoplasmosis with azithromycin. N Engl J Med 1994; 330:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/72\">",
"      Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol 2002; 134:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/73\">",
"      Derouin F, Jacqz-Aigrain E, Thulliez P, et al. Cotrimoxazole for prenatal treatment of congenital toxoplasmosis? Parasitol Today 2000; 16:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/74\">",
"      Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 2006; 107:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/75\">",
"      Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/76\">",
"      Berrebi A, Kobuch WE, Bessieres MH, et al. Termination of pregnancy for maternal toxoplasmosis. Lancet 1994; 344:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/77\">",
"      Freeman K, Salt A, Prusa A, et al. Association between congenital toxoplasmosis and parent-reported developmental outcomes, concerns, and impairments, in 3 year old children. BMC Pediatr 2005; 5:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/78\">",
"      Gollub EL, Leroy V, Gilbert R, et al. Effectiveness of health education on Toxoplasma-related knowledge, behaviour, and risk of seroconversion in pregnancy. Eur J Obstet Gynecol Reprod Biol 2008; 136:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/79\">",
"      Dubey JP. Toxoplasmosis - a waterborne zoonosis. Vet Parasitol 2004; 126:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/80\">",
"      Dubey JP. Strategies to reduce transmission of Toxoplasma gondii to animals and humans. Vet Parasitol 1996; 64:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/81\">",
"      Warnekulasuriya MR, Johnson JD, Holliman RE. Detection of Toxoplasma gondii in cured meats. Int J Food Microbiol 1998; 45:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/39/22137/abstract/82\">",
"      Fayer R, Dubey JP, Lindsay DS. Zoonotic protozoa: from land to sea. Trends Parasitol 2004; 20:531.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6756 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22137=[""].join("\n");
var outline_f21_39_22137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MATERNAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FETAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fetal sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RATIONALE FOR PRENATAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Spiramycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pyrimethamine and sulfadiazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TERMINATION OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546172\">",
"      NEONATAL MANAGEMENT AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=related_link\">",
"      Congenital toxoplasmosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7672?source=related_link\">",
"      Congenital toxoplasmosis: Treatment, outcome, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_39_22138="Triatomine bugs";
var content_f21_39_22138=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Visual aid for the identification of triatomine bugs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adult triatomine bugs are typically 0.75 to 1.25 inches in length.",
"    <br>",
"     (A)",
"     <em>",
"      Rhodnius prolixus",
"     </em>",
"     adult with eggs, commonly found in Central America and northern South America.",
"     <br>",
"      (B)",
"      <em>",
"       Triatoma protacta",
"      </em>",
"      adult, commonly found in California and Arizona.",
"      <br>",
"       (C)",
"       <em>",
"        Triatoma dimidiata",
"       </em>",
"       adult, commonly found in Central America and northern South America.",
"       <br>",
"        (D)",
"        <em>",
"         Triatoma gerstaeckeri",
"        </em>",
"        adult, commonly found in Texas.",
"        <br>",
"         (E)",
"         <em>",
"          Triatoma sanguisuga",
"         </em>",
"         adult, commonly found in the southeastern United States and Texas.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Centers for Disease Control and Prevention. Available online at:",
"          <a href=\"file://www.cdc.gov/chagas/resources/visual_triatomine_aid.pdf\">",
"           file://www.cdc.gov/chagas/resources/visual_triatomine_aid.pdf",
"          </a>",
"          .",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22138=[""].join("\n");
var outline_f21_39_22138=null;
var title_f21_39_22139="Criteria narcissistic personal";
var content_f21_39_22139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for narcissistic personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Five or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Has a grandiose sense of self-importance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Is preoccupied with fantasies of unlimited success, power, brilliance, beauty, or ideal love",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Believes he or she is \"special\" and unique and can only be understood by or should associate with other special or high-status people (or institutions)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Requires excessive admiration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Has a sense of entitlement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Is interpersonally exploitative, ie, takes advantage of others to achieve his or her own ends",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Lacks empathy: unwilling to recognize or identify with the feelings and needs of others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Is often envious of others or believes that others are envious of him or her",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. Shows arrogant, haughty behaviors or attitudes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22139=[""].join("\n");
var outline_f21_39_22139=null;
var title_f21_39_22140="Risk of thromboembolism in AF";
var content_f21_39_22140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of systemic thromboembolism in nonvalvular atrial fibrillation from the SPAF-III trial in patients treated with aspirin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Thromboembolic risk, percent per year",
"       </td>",
"       <td class=\"subtitle1\">",
"        NNT*",
"       </td>",
"       <td class=\"subtitle1\">",
"        General recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior stroke or TIA",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        Warfarin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Primary prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        High",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"       <td class=\"sublist_other\">",
"        33",
"       </td>",
"       <td class=\"sublist_other\">",
"        Warfarin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Moderate",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"       <td class=\"sublist_other\">",
"        66",
"       </td>",
"       <td class=\"sublist_other\">",
"        Warfarin or aspirn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Low",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        200",
"       </td>",
"       <td class=\"sublist_other\">",
"        Aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Definitions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <strong>",
"         High",
"        </strong>",
"        - one or more of the following",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        Previous thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        Woman older than 75 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        Systolic pressure &gt;160 mm Hg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        Heart failure or severe left ventricular dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Moderate",
"        </strong>",
"        - none of the above but a history of hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Low",
"        </strong>",
"        - none of the above",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * NNT: number needed to treat with warfarin rather than aspirin for one year to prevent one event.",
"    </div>",
"    <div class=\"reference\">",
"     Adapated from Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633; and The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998; 279:1273.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22140=[""].join("\n");
var outline_f21_39_22140=null;
var title_f21_39_22141="Silent ischemia CHD mortality";
var content_f21_39_22141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Silent ischemia increases mortality in patients with coronary risk factors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 299px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 2682 men without known coronary heart disease (CHD) followed for 10 years, the presence of asymptomatic ST segment depression during or after exercise exercise was a predictor of CHD mortality in high risk men; this association was not seen in low risk men without risk factors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Laukkanen JA, Kurl S, Lakka TA. J Am Coll Cardiol 2001; 38:72.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22141=[""].join("\n");
var outline_f21_39_22141=null;
var title_f21_39_22142="Lipid lowering improves outcome after CABG";
var content_f21_39_22142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Aggressive lipid lowering improves the outcome after CABG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Post Coronary Artery Bypass Graft trial, which enrolled 1351 patients, aggressive lipid lowering therapy with lovastatin and, if needed, cholestyramine insignificantly reduced the composite clinical end point of death, myocardial infarction, need for revascularization procedures, or stroke by 18 percent at the end of the trial. However, at the end of the 7.5 year extended follow-up period, there was a significant 24 percent reduction in the composite clinical endpoint (p = 0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Knatterud GL, Rosenberg Y, Campeau L, et al. Circulation 2000; 102:157.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22142=[""].join("\n");
var outline_f21_39_22142=null;
var title_f21_39_22143="Calcific tendonitis AP view";
var content_f21_39_22143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Calcific tendonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAfQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAoopQM0AA5qSOMntT4481bihoAjji44FW4oenFTQw9Ktxxe1AEMUNW448duakjiz1qzGnpQBEkXTI5qeOLPNSIvardpD5kqqOmaAJ9OsskMRW6DtTZGcKOSfWo4kCxhV6Dj61PCBwW6DtQAwE7Qc4/nTTKd2P4ae6HPzHI9qY8RfBQ8UAIG3HGc4p0aM7YGRUsdsTnZx6mrUSfJjGKAIFQRDIOWpyAtk9qtfY3Y4RSfersWnt0AxQBTjjyAFByasqmwhX5FTqET5QPm6ZFSCMY3+lADAyqpAGCKhaVm4zxSyFVySck1EXULlaACV2AzUkExkjGQNwqB5MjGKiiZo5NwoA0drHsaUEkbcEGoEvXzyvWnNNJnIUjNAFmNDkscE9jU8afMMNnP86zw0hIPT2pCLhemaANfyQGBYKDnuamRYg4BkBHfFYeybcMsamjaSNeM80Abpkhi6c/WnLdKVyu0Vi5Z1GTQ2U7mgDolu/l3PID+NRDUkD/e/WsNHwMHnNKVGM4PFAG0+pA8q2aRdXCsB79axkGT1601iVfBFAHRDV+AMtSnVyD8rkH3rE4Kjmo25fIPegDpU12VTgvxVy38RnIDOuPpXHnOOuaRgd3WgD0i31qFwA2AT3NX/ADI5lyjD6ivLobuRBwc4rTs9adAN2fwNAHoQgBT1NOihGMMK57T9fG1cjP41u2WpwzqTnB9KALL2idetMNgsmQRg4qwlxEQOfrVuFlznPXtQBlNYMBhA3FEFrIG6H8RXQRoO3ep44QSMADHNAGOtq+wlgaYI3jUqe361v+UAv96s+5Tk8jI60AZxEf8AETn6UVM8YLZ4ooA/PGiiigAooooAKKKKACiiigAooooAKKKUDNAAAT0qzFCTzinQQg9etXoIc5oAZDDz0q9FDwOKkihx1FXIYhigCKOIVajip8cQqwkdADFj71Ki+g5qVUzUyR+tAESJz0q/pqhZ1yOtQKnPNWIQQwYdRQBrxqfK6VKkZKg4/Ki2dH2tkfMPmBrTSW3hjwPmY+vagCotqzKSFPFPg06YncVIX3qZdXdOMR4HtUra2rKA+APagB8FiFJLuFA9asKluvIAZvT1qh9shmGA559aaTydjr+dAGrHeGPhEUfhTJbssD8wzWaHf+KQfgaN0IzmSgC35hbHQY70ydpCAEORUS3dtGv3ifpTTqsUf3Ez9aAJo7WSUjKnBHerUWnbSC5HSs59akC/KqioJNYnbkdaAOj+xwgYIX604W9qo5VfxrlW1CdxncfzpDezY6k5oA6srar0VKN1v32muT+1ynGTTlvJAKAOs3wYGAvHtRuj7jiuXS+f8qmS+PegDeKpnI6U11XHBFZcd7k4JFTpcD1oAtbD1zxSeWR15FNjl96nVs9SKAItuDnFOlB2jtUow2QetLtGf8aAKq5ByamkUMBg5NTGMYHAxioHRgRwcUAJGSHANSGP5uOO9RiNtw9OtWGz5We4oArklTgU5gCvBwaVRvYZ6ihxjrQBXOQaVGyCp4p24Fsf0oYc4xigB0Uzo3ykitO01QoAHJBHesgdfSlH3smgDs7LWTgfPkfWtmLWFyBvx9a82DlT8hxVpLuQYDHOKAPU7PWRnls/jWvFrMZ64/CvHotQljPymtvTtWDHGeaAPTf7RST/AFbVCZQ2fmzmuXtL0MoINaENyR0PagDReQBqKqfaPWigD8+6KKKACiiigAooooAKKKKACiilAyaAADNW4YuhxzSQxZxxWjBBigBIIe9aEEXQmlhix1FXIo+OlACRR57VZjjxTo48YqwqZ4oAaielTKntT0Q+mKmVfagBqp09qkCnoKekeBUyp0zQBGi8c1Ii8U9V9BipAmBz1oAapI6ZFPJY8ZpVU+lKQQaAGgcU7HSlxRQAg6+9O59aAOtOC9OKAGgt6ml+Y04CngcUAR4OetKQeKkAweaUA56UARbTil24qUL82adjnmgCMJ1ox2p+PSl2j0oAiCH8aco/OpMUoHNAEYUjrTiM0/ae/SjHagBuMdKkVmToaAuaGGeRQBPBdMCAauw3QbqazMdxSjOeO1AG/HKKsKcgEdKwobgqRk1pW0pcgLzQBpLyvpjmnBCxwOaSBMj5qvQqONq4JoAqrAwJ6D3pzW/ykdzV8QljlhhfSlNv6ZOPagDIFrtO7PIpssJI3Z5rVa3IPOcHsKDbDBGMUAYTQHdkduTTHfk4rZe3CHOetVpbVH5xQBlsdw6U0HGQfzqzLblCQp5qGSMgZxQA0DPfpUynkH9ag3e1SbgRz1oAlyegODT0Y5+XqKiA+XP+cU5SMHHWgDZsNSKAK54z1rorS8DDAPFcLk4H8qvWF48RwScUAdx9pxRWFHfZQEMOaKAPjGiiigAooooAKKKKACiiigBRzViCPvTIE3HkVo28XPSgB9tDxk1oxR/lTYIuBV6GPgUAEUfSrkSYHSmxxnPTiraJQAkaVYVcH6UqKKmiTPOKAEjWpkTipobdm6CtC3sckZFAGcsZ9KsJCSfpWulmo/hFP+zAHpgUAZkVuSOetSG3HXp7VqGBUU7cZqB0/u9aAKZATGRUchDVZdcjn0qFUAyWoAh28cUuO9SBMNmlCjHI5oAiQZJwOaeUJHFPC46U8LQBEF9qftOOlPC8804LwaAI8etKAcdKkCU4LkEDNAEQHGcZoK9+1S4wKAMigCPbxx1pVWpAvHHWlI9B9aAIgCD60pA9OadgZI70Ac0ANA+XBpDz1HNSEYpMUAIowMmlxxQF49s0oXHWgBMUY7YpwHzYq7BB6gUAQw2zPjsKvwRGLBU8VNGhJAwavwadPKg2oaAJLXawBbj1rTtwBjB+lQQ6RKpBb8s1pW9m8TAnaCOmTQA+ONmXI4qXyuGIUmrMFsmP3j8+gqZpFAwoAAoAoMhVQGHNU5kZSdozWsZATzgmqsxXk9B3oAzXQ+WC+P61VcjOBjrWk6gqSFHHSqrRDdkgUAZ8qknoBVeWHGSDV5lLAkKee1Qsu1Du4oAzHjCZOM03AK9Md60Hi4479hVeSM56flQBAjheKlOMZFQldpIOR6VJECSBQAnOSadHnFSrbuxHHtV23sTxuBz6UAUw7gDb0orYS1Xb92igD49ooooAKKKKACiiigApyDLCm1at484NAE9tFWpbxcioLaPitOFMCgCSGPgVbiSmxJwKtxLQA6NckAelWY1wBTY1x2q3FGSelACRRZPrWpZ2fygtmn2VqRyRWtDBkCgCOC1A7VcihC9etTwx7QM1OYiRnGKAK+FGPao5yD93v6VLOAB159qrs6ovXLUARElcbqhlkGKSdy5J71XAycDrQArsSDTMZq5DZO53NhVq9DHDF91ckdyKAMyO1ldvlU49atx6a2MuQKvhucdBQpyMmgCBNMj5JfmpVsbcDBz71Lj1NL/CPQmgBBYWxXIBzSnT7dlxgg1Ko4Az1p4zjk8UAV/7JhIyrsKifSGHKuDxWgDnrwKcjEcZz2oAw5bGaPlkOB3FVim0811YY455FRTW8E6/OoDdBigDl9o5oxite40p1GYTuFZ0kbIxV1IIoAhxxQAMU7tQBQAwgnvTQOMflUhzQAKAGdqcAKXFWbe3MnJGBQAWkW47z0Fbem2DXI46E8Uul2BkwSPl/nXU2YS3CjAzQBAllb2Eau6bpD61VudSbcFVQAOlW9WclSR0rnskyEn6UAXTfzkBmfA9KaLqQncznnnrVMhix/SgMDnOc4oA1ra/IwCcknFaSXG/qfbFciXK8JyfWtKzuyzYY9BQBv8AmDcOnNRyMORjrVWKbkc/hU3L5JPFADJCc4PAqs/XIqzJHkDPbpUDrgYxQBECM+tJNGHGO2PSncBs9qmRN5BY8UAURFkDGeKsLbLIAcHPpVwKmMBeasxx5ZdmcHr7UAZg0pJR82QRT10yNfur1roLW0Z29DVr7OsbDzOBQBzSWe3AIwKtwwcfKua0pntwTtwcdKQ3cadBjFAFRbV8fdxRUVzriJKVB6UUAfFFFFFABRRRQAUUUUAPRdxrStI+nHFVbZPatW1TAAxQBat460IUyRUEK9KvRLkigCWJOmatxr7VHCvGetW41z+FADoYyxHv2rYsrXA5BqKwts4OOtbtrB0NADreDgcVoxQ/L0pIo/XFXI1zQAyNAKJ2Krx09Ke+EOT0qtO+ckHj0oArTsD14rNlbnuanupTwBVVFLPj1oAEVpHwoNXIYo4+gBb1NSJFsXHT1NKg2kd896AH7mPfilUjjPQ9aQKQTuzSoo5PbvQA9cdfSgHI54GaF+96UwNyVxQBOTwakTHygdqj4JBJ49KdkBsigCVeSMdc04A7jgcVCuMFu9S8Nj3oAcCdvH45qRDjd7VEDg8g1IhAXdgn2oAkBODge1PAwuW60kYLMW/HFSMR0zzQA1WOeKbJbw3GRIuDj73SngAY7+tBPtQBh3tg0ByPmU9xVAj9K6wdApGVPrWZqOnj5pYeh6r6UAYx4pAMnGOtSKjMcAVYjjWJeeTQA2G34y3WtOyhErqgOFzzVJWY55rb0WH9w8g5waANMNHAiqv3V4FMEzbt2aikyYuDTQpIxjtmgDRn/fwgjr0NZE8RRyMYUc/Wr1rIYk+YHFSSwifnrn0oAwmbAJ5J7UwNj5n/AEq5PaPGSV+7VORdoAbr6UARmQKcgfhUXnMjhs9aWQ/P8tRSR7Blj16CgDZtLrci5IzWrFJux2FcpayeXIO+ePpXQ2suU9+maANPKviopoyFyOR9KWMDaMHPtVgRlsYHTpQBmSKyjnHBpbeT5iuc57elai2nnHDtj2qvJaRRSBx1HvQA+0gLsVOcdzWnbWwhxyGzVJJC8ZMZxjritC3x5Q3c5Gc0AXIZwkZZsADua57VtUd5H8pvlzVfWdS3N5EXTHOKoxIBHl+M+tACLcyMw5JNPmuXEZGTmq0syhvlGAKqz3G7IzxQBVnkLSk5NFNJBPPWigD5fooooAKKKKACnIMtTangXJFAF21TnNa1snFUrVOK1YEHANAFmBe2KuwrUMCYFXIVoAmiHFXrWHc/TNVolFbWlw559aANOzg2qOK1bePgccVBbJgc9KuRgfhQBMqAdRUcsuzIUjJpZZQq8HmqbPk+5oAlVic5Y1DK/BApN21s5pY4jONvqaAM+RGkkwoLGtC1svIUSTDk9BV22tlgTJGDTLpy43UAQHByRzSYKDIHNM3ZPHFPByfmoAXll5IpFDMDyKbI3GD+AFKDhh6YoAf0UZFRMvzA8j60/OW54xTXcc45z60ASITsJPrUgYBlAHGKiTBTBPvRuG5QvWgCcHK7f4qemdgZeoqBjtfaBgetSRZG9VPHXNAEyEk5PWpIyQ3U49qhi69c5FSk4HHHHagCxGSM44/rSyH5ee/U03I2qcnJ4NDD7ucnNAEqDJBocjn9BTsfNhetNIGfegBdhIyBwasQQZUFwAvoakgVVQetTMCqHt6CgDI1KxQjfbKAR1ArEb7wJ6dK6sHHPb371j6tZ7T5sf3T1HoaAM0KSflAFdXoaL/Z0i4+YnNcorFOG9a6nSZxHbjgc0ASRxBnKfz7VHIvl5JOTWiVCkAADNVL2PbyCOaAKBlbPPIPbNPhuzG2BnHTFQyL83vUIJV2AHNAGv56OoD4Bps1tAwDAgms9WJyHzmleRvL+907UARzWLFtyLVC5t3DEyKRWnDcyDr0qz58cgxIgoA5UBt5wSea6PSld0GQTmrMVpZPIGxjPeugs30+2jATGcUAVraEKAWzirR6bQMc9qd9vskOMg/hSPe2xjJVuaAGurBgycjFRPbNITxgnrTlv4FAAAPtmrX2tBgjHI/KgBlnbCJNpGc9jUeqTpb27ohCk8U281AxR/LzmuZ1G+aQsWNADiYg+9mDNVa7vNxwpwKzJbpiSBUKS5fLHigC3NN8vB5qEN/eqPeGJA7UjmgBzNzRVdmOetFAHzdRRRQAUUUUAOXrV21T1qpEMmtK3XoMdaAL9qnFakK8CqlqnStKFORmgCeFenvV6JORVeFec9hV2JeBQBNCnNdBpqYU49qw4xjGa3bN9oDA/hQBsRYCj2p804RKq+ZlQRVWaUucc0APNwWfnOKFdmbC9RUcUTOwCg+9athaKCM80ARWtu7sN45rWt4ggH605kEfPrQGUKTznpQBFcfN3+WqchypHerLHPeqswCqD1oArFTj2pACO9LnmnYO3kjJoAYTuPvTlZl/wprK3+RSAkdSOPegBd248gmjZz1py8gkGhCTjH/66AHIRgnHAp6Yz8uc1AzYU4FOiPOcmgB8m9iKsjap2kckc4qBBkfPwc1d2DO5l59aAGJ/rcKaeuVJAOfrQy/KWHXNSW8eYyW+UUASR/M4z/8AWqXdlsdhUZiO07SQtOUAJ8u7A45oAerk/wAVPI5wO9RiM/e4yelOUbeDyR1NAFywUjIJBNTzNuQkjGKhtyFYFetE78lVOR3oAiY45zke1AIKMrdKQ8D5QAO9MG7JOelAGLe2zQT7Typ5BrUs2H2cAdBS3Uf2iEgr8y8ioImCIFJxQBv27rcW/BO9BVWcF8gg8GmaVMsVwPmGDwcmr16uyQAdD3oAyZvv9Me9QElRuPWrN8rKwx09arOhY5LDB5oAYwbIJYYpMKhDM3HpRPLGiAAgYrNuLslSFPHWgC3LOvPOBUJvgo4+b2rJadnPJpyqVXcQR6UAaSXcjnBPFXbS6IBXNYiOVIbH51NbS4kOetAGlNMQ4OST3qa0nLo+MjnFUGdSrHv25qbTZAwcZ280AakMiA8+nep1vFGTxis2QYxtqMuVynAoA0Jr8FeeRWNduJCdvFJPIApUnmqbuWU80AQyK2c0Dp1pssnAC01HGfegCwpCjjrSbsAk1EXpGbINACFiSecUVETzRQB89UUUUAFFFLQBYt1rTtV5WqNsOma1bRecigDRtl6ZrRhXoap268VowrgCgCxCtXI1FQxirKLgCgCRe1XbeUp06VVVfap0FAGiJy647VPAjSMMdKoQBiQAM5resocJhe3WgCxDCqKAvDdauoQigg49RVdsKhYnnpVfzvmwTxmgDQll39sD1qFDknk1BLINoFRmUDoeKALZ4XAP41Vl6ZJ5p3mHgjvUEj5bB6CgBkhyucYphB2jFKTknHIFMJI+lADxMV4INLlX6DFNQh+TzT0VcAjg0AKihRk96miMeSrD7vQ0xGQn5utSsgCgg/KaAIZxufC8gU5V8tCStSxxL1yaUqW75HpQBDuYADbVl5trjr9KhkUqMk+4JqGFmeTBxnNAF532cD7p561O02IkTbjPOapO5ZscYBqWZ8bMc4HSgC5buzY3fcz0qeSQYwOuOlU42K4I9uKSR90mQCOcUAWgfu4BzQJMMB70iOUTPUmmcqBjr3PrQBbRsSbz27CpM5f0HeqkcpRgMBm7irG4FiWz70AK4A4GR9O9KTtUkjH070hKFvlDEChmG3P6ntQAI2GVj69DVbVIRDMGHR+RT1yX/HNS3q+bCU6kdPWgCjb8uMV0D5ltkkPJUbSK5iPgjB+Ydq6GyuFEKK5GCOaAK0gEgO4n1rLvblR8qrj+lXr2YbmWPArDlBZjn86AIJGLfNmq0n3u+DU8g28Mc4qvNJngDAoARgsbZxk44pDcFuCelRglhgHJ96aq/Pz1oAkWTLHPIp0b/N1xUbr8x54pxBxxQBejcSfKTyBxU9t8hBGcGqMagbWDc4q3DKSCF9eKALwnBI3ZzVe4lKS+o9aimyJO9V3mzkE80ANuJTng1EWJTIP1pX+cA9/WonYAcGgBDjdQpAU+tV2k+Y4pA5xQBZDEk0b+Kr7sL15ppfg0ASF+f/r0VBuooA8HooooAKcgy1NqWEZNAF6AYFatmOBWdbjOK1rQcCgDRgFaEC569KpW65FaMK4xQBaiFWVHPNQxLzxVhR+VAEi9Pap4+MY71EB0qYdOKANK0IUZx2rThmC8KOSKyLZzsx6VoREKu49aAHu5IOTznpUanJ4wDUb56+ppv8XXpQBYaQkmlP3cVCGODjrUpOVBxzQAjMVI+bFMznPWnOcgg0xcgfSgBc8cGlzlTkcj0oxx2NA4HPegBQmc9/pSqOMDNL0GacHJAyAT6+lAArDvwamxujAY9KiAMpGwDipSCiDPXFACqflwDT1yqbsjNMjTC89c1IhQHkk/0oAVpd8ePQ8U2PCZJUZPSkZhgBQKceOX7dKAHRwbmyT8o5pWVWZijZxxiommxKOeO4o8xNwPTPOBQBMk3PQDBp6yqHOck+1NCoyHbwc81GrMXwpAFAFoOzgkY29uKcN4wWbAA4HrUKthlQnkc0CRd/TJ6c9qAJImYuTwGNWUcjAPJ7mq4TcBtOBTnlYDapG0cc0AWmfaMDPNIeQM8cVUkmGFOSMcfWkEhVc9/c0AThmB4zx39asFi2Gzg9MCs8y+Y3B6elWZHbaBtA96AM66kWC5YdM8gVPBcllQntVPUlO5GxliMVHbSY+UkjHYUAblyqna4xzWPfsVlIXgYrSjfzLQc/drN1AnZwKAKL/3iR71E4G04GakAz16elNUYf5uAfWgCuoJODwBTGcq4CVZmT58r90daq5Uyck49qAJZtygZ601NwBLVLdIeCOmKdGpMZzzQAkAKN32k5q2DtbcOlQwHoCCat43cY4oAdO4wu0ckZqjKo8zOOKtynoO4qF8YOOtAFeTABFV5eakfoSe9VpD70ARFhmgkYwailYBqjL5NAFguM4oY8AVWzk04tk0APJOeKKaCcdM0UAeH0UUUAFT24yagq1bdaANCAcita1HA4rNgGK1bMfKKANG3HpWlEOlUIQcVoRjgetAFmOrCjpkVBHxVlDxigCRe1TDiok681KBQBZtPmfHqK02GI8VnWB/0lB2Nacy4OPagCNunNQ9T9an7YNN4Un1NADoxnmnE4+tIg45707rxigCF8nOeKORkg07BJPSl8s5znj0oAYuSwJzmpSM4z2pFXkYp2NzEZzjtQAFcikGcYqdk44OKYI8sACKAHRA4LKOlSuMjcetINqnAPNIRuU5PQ0AIGYr6c00DA5HWhG4Jzk0+M5+9zQAq/kBTWzxTj94g9KdvRvlYY47UANAxliBmk3KW4XpUxQFABnr2qEFA7YB/GgCWNtvJojT94XzxQEJQN/Ce9NPLAn0oAmhZsEhQT6+lMSNzIGI6HnFETduQDTg+OA3GcYoAe0gTnk+1IkpcE7SBnqaRcAkgg49qJCSCBQAZbIxgk+tKdozuOagU84J9qcwK8HBoAcx4+Xj6VbVmEKbiTxVHOOpwatJIBbjJJJoAr6iP9G3YPynis6JiTkVo32WsZcnjrWPEdjA5OKANuybO4Buo6ZqvdnDsp5WksWUSjA4YU66ABPYH2oAzpXZORj2qNmLhXyOvIqRxlcAgnPWoki8tjuPXk0APkcYK4wKhSFTKCOc0y4OM4+tS2bkEEjAoAdckk/KM9qkg+9tYcGhlLElcYPNOAYYx0HrQBOIsE4BqwGO0Y6gVGsx2ANwAKjkmwDgUAPkx981Vkk25weKesu9TxVWYc0ANkbcfrVWXg1O/YjtUMgyetAFOXO6otpzViRckZphBB5FADRTj9BSHtT41zjNAEiIdooqYDAooA8EooooAUdau2wHFU0+8KvW1AGhD1Na1p90VlQCtezHyigDSg7VowjoBVC3A4q/CMcjrQBYQdMVYUfN14qBAMc1YSgCROfpUoqIdKkUnjPWgCzanE6HvmtuYE447dawYziRT6Gt2QkpGR0xQBBLlcmox0yeTU02WHp61DjPUnNAD1PTinE8g0IAVyDjtQOXHHFACN14pSwAyc5pz4DZNRldynOaAHhsgHrS5IcE9SaYgK49BU8Kln5oAnYAEelKyqq5A5NOlXacjrUXJ60AMcc1Gc54qQ5Y9OKhbIfFAD4/QAZzRJw4GaAOPf1oIDOBQBJ04FMVcEluaeMDAHNIo2gk9aAJEbH1FNUkt0zml5wD60bcZYMTxQA5ywXb2p8ZUd8momJ681GGIOeST0oAnJJUHpzTV2qzZIPPamu5C9eetQgHdubqTnigCYPkFV5apBISmG61WjfEjMRgGpOGJwePagB5BUfNj2NAmHIccnocVCzhOAMqaiJVjyG+lAFkNgDCj6mrKsDBnaODVKOQdWJx6GrUT7ogEbjPIoAbc82cuOMjvWKGww55rYvZB9hlByCcDJrG3dMjPvQBNDJ+9XBPBrRncb+RkVjptE/OST6VpS4cqN3UfjQBTmZVkbHOe1Cju4yCKJUAJK5J7mnx+poArGMkn0p4ZeNvWpmHzDGMelRMmOQAPQ0ASBtpGRxjvUv3gGHSoMhvvHnNTxjKcdKAAtkkDOPeo5CeKlY4PHNMbDr09vpQAwEgYGBmoymTz1p/OeePSnYO7PYUAQMuBiq7LyDVluTmoth3Z7UAVXXJpjIcnmrTr831pjKRQBWK8YpyjvT8c9KcFoAUA46UU/YfWigDwKiiigByferQtv51nx/erQthyKANGAYFalnWZB0FalmOlAGrB14q/F90e9UYOtXoe2aALMY4FTioU9KmWgCVenPWnqcqMVGuakUDPHQ0ASLz+FdBYNvtASeV61z69Oa2dFkBV0PQ0ASSLwaiVTk55qaV2BPHGcUn8II4zQAzaQpwOBTh0yRUgUMmOKbtwODkjtQAkg3JnFRxjkDtVkHCc1GUKZb8vagCTaB16dqnhGJFz0qtDlvvdKnjYqQcdTQBPc9Sfbiqi5yc81dlUsM+1VMc9aAI5XwpweahXHfrUjrhTjk01VAxkdaAEAOSRzTl+8KDkYxnFKvLdDwKAH5G4n0o2/LzzmoxkKevWp4uRz1oAFHQY4xTgvGFYGkfAI96aJMZAwKABsg4GPxpjfJgKafkNjB96jkwe+AKAEnGR1qE9jzgVKSBhQeoqI529aAEjIc8ZwPU0olEbMVpqsI0IyCTUDMcnB5oAsGUHqcU+GUMefSqO8r96pEI3A96ALLsrMcEip4WG3DfmKpggn09QasJnA2459aAGak5Fqfm4JFZUbMRwePermquBGsfccms0OW4FAFxBiTNS3LOZFwcGqcLHzADmrV3J8y4AK+tADXkO3k0+J/k+f7tVZnGzC/pSBgU2huaANFGAB746U+XEkYCiqERYHuF96vw4VeBk/nQBF5JGMj8asRjbwelWPL3qB09qY8BTk9fWgBrbMHae1MHyHtzSbCqt60qDOM80AIw3KRgCoSrYxmrCxnqelPNvuGRQBTC4460FQAcVaaIJ1FRtH1x3oApsuelRkENVgoRzUZGeTQBXKjn1pyqQM4NP2/NnuacBgYoAZk+lFPAyO9FAHz3RRRQBJD96r8HWqEIy1aEHagDRhzwK07Q9BWZEOBitOz4xQBrwetXYfwqjBn86vRfdHqaALK4qdSM1AtTryKAJRwM55p47GmL0FSDNADwauafLsuV9zVIDjipYztIOe9AG9cp1wKiDDHbpVoHzbZH68VUYbWI6UALGQCBSg4c+ppgOD707B3ZHWgB+c9fWnFQRg00EA9akUbgcjvQAnfgU4A7eeAKegJIHSpGQMhzyPSgCwih7fg/jVRgFx61egKiBkA5xVVo+enHfNAFZhk88GkK4yOKmIXocZqFxg9elAERJBK9QOhpY8k9eM0FW3ZJFKhA6mgBwGQR3oiJB44ppPOaeMbqAFcljxUQB3HiplPB4pMY7UANTKq3pioZG46ZwKlBPOelMIDLwec0ANGPvH0pkpwBmpAnzMOo9KinB3+mOgoAruyg81FuBc+mKkdckmoZF2c859KAEeQHGc+1KJGDZxgVXkfA6cimAuRgdqALYmBY561fspBIOTwKx4lYsODmrkUy2ylSw3MOlAFbUZd9wx5x0FV0zn5RUtymWPPHWkt1LHnpQBPaEKC0gBApBtZyQxw3GKb5g7jjsKYm1z1I+lADpgEI2YPrSxR7ju2gGgq3BK5FTIGA56elADg20c9BVqAnqpz7VX+RwF5GKs2ke0kntQBpWyl2BJGRVkxhyQeoqmsuR8pxU8Ttyex60ASfZlZcCq5twASBWhGucHoKnVAyFTjr1oAxgpHakxtbjNX5YGVunHrURjx2yaAKxUMnzdqhdMKRV8RjoB1pJ7f5cigDLKnHI4qIxVdkTsKQR560AUPLIYjtSbccVcaI8cVEy45oAh2UVLgUUAfOFFFFAEsH3q0IKz4PvYrRgOKANCHoCa0rPk1mRdq0bTO4Y6UAbFvwKvQ9vaqEGelXoaALSH86mTpUC549anSgCVcgVLkdT0NRKQOtSLyeKAHr1FP71HUi570AbujSh4jGe3SpbhAO3SsrT5vJnUk8dDW3cAHBX7pFAFLGRzSqCWGOopwy3HpSqcDpxQA7ZkfNwamjUAYznNMU/JnvT0bn2oAlXgggZA7CnEnDYGOKFIVSUPJ4PFEQ3My5PIoAdbkbhnvTbsgZwKYu5W4HenzYYbyelAFPHIxQRnqOac3zcilbHcY4oAgkPJx2pkbbnFTOp2jjg1BsKnpwKAJTnng9aVF+U47UxWI5JyDUp60ASRqcgY+Wg4BLY4oBKrxgmo95dcEYIoARgNuTUSc57YqReeOM+lNfG1+OnegBseAxxnJqO4HJYdfWmoPnBU5zUrqed35UAUpd2CQc+9NRWcAMQTVpoumRmkWIs2BwB39KAIBbIW6j6U821vGC8hwvpmoL+/hs8pD88mOtYFxcyTEtIxY0Aad7qccW6O1QYH8RrNglaSfexPPrVRutPt2AlGelAG+MOAJBx2NPW2Hy4yR2qlHMHAXHI71o2svlL83I9aAIpIWHAA+tOjiCxnpuFJLIrMSpwT7VXlvUibG4HFAE8jMFAzxTos7cqoPvVJtRgY5fj6VatdUgVc7dwoAtxI0hGBg96urbsoyWyO9ZraxHj5VOahOoyOepFAG2GRQFYfjmnLNsJ/u1giVmPJ6e9WI5GB4PFAHS204dQBV+LBUn1rmYLkggHrWpZ3TKAeo9KANZVyOeR61HJAGORwafGyyrlfy9KnXgdKAMyRCjdOKZKx24NbJjWReR9DVGa1IPyYOaAM4oH4I5phjwcccVaK7X5BFDpuHHFAFMoM+1QTRgAg1cK4PIprRk9OlAGdtPbP4UVd8kZ7CigD5eooooAlh+9Whb881nRferSg9ulAGhD0FaNocECs6A1fteWGKANmKrkRyeapQ+1XYunHWgC1H71OvSq8ZzzU65zQBMtPBAJqNeGFSDrmgB4HPJp4/Wo/oacp5xQBOpIOa6LTpBNZANyw4rmlNaWk3GycDsaANARlWJxTXHymr0qA8jgHvVRlwTkUANQYUinIccUIODmlAwN3fpQBLHtKkg8+hqRU56/Wq6EjGPWr1qm9mTjcwoAhlK+XgcHPFNAAU7jwalljHzL3XrUIOSRjigCJl2t7e9Jndg96kkG75R1HeoenBoAVlPQHNIVO0UoYKc0/duHHBoArhME5xipOCPQ05zgjjJ+lLswRnoaAGjhhzjIpM+mKbLy/HpTI2zwBzQAsWRJkjg8fSpJRjf3BoA4waGxsOevWgCvAnz4I/GpypJUDknrUsMXyjrluDUptzEu49QKAKFypyqr07msnVdR8hDFBwehPer2o3IhiYnO7pXJzyGSUseSTQAxmLksTknqajLYNOI7imN1NADScmmg8g9KUikNAE8c+xssD+BqX7e6japIHbmqPSmk8igCzJqMz8ZwPYVVaRnbkmlwD0FKq4NADefc1NFkEc00LzUiKM9aALULDPPSrIxVVV4FSoxAx2oAtxnA4q5C24DsaoR/MAM+9XbZTtGaALqt+nSrVvIylapfd/GnrJz6UAb1tc4OR071pwXCyBQTn2rl4Jiucc1fguemO1AHRggfcPFP25wQBg1k29yevX61pRvvC880AOktVkXdj8qz5beSM8Z+lagJwCOtSDYc7wDQBhyRFhk8GotmBjGK2Xgzk/lxVeWHJye3FAGd5YPUCirZgGeP1ooA+R6KKKAHxferRtzWbH98VoW/TnrQBow54zWhankVnQE4rQtjyuaANqA9MGrsfGCaoQHpV1DwM0AXI+lTIeOarp24qZen1oAmFSoeKiWnrwKAJVPWnL15pq/SlFAEg496kjbY6kHoc1CO9OH60Adfp7i5gxxkDiiaMjrWRodyUfaTgdq6OSMSR7xz3oAzAuG56GlGN2MZ4qR19aYv0oAaVGzIFSwSbZkI6UAKY+PxqaBULLu4oAfdhVkYA5zzVMttPtV2UKZGXow4qnKByCOc0ARlh1xg0MoYZFNYYU/zpiv8+O1ADWHy980I+0inyjcagfIPAoAtqyucHtSupK1VjPOe9T+ZtUZPFAEeCOtQjiTjpVncCPxpEjLtgjigBsbMck9qnhiMkygjg0hjVU5zzVuL5QuO3egCcIolC8cCq2qTqqhcgY5q7MBGC56npXK65c43Y6UAYmr3RnnwCdo9KzSeaGYsxJ9ab6mgAPamn24oPIphIx70AISab1o+tB6UAIenFIBxSjmnAY+tACAUo60u3uTTsDIFACDg5/Op4wDg0xADU6jGKAHAU9QB2pFGeak20AKoweKsRTMuPmPSoF4pVFAFwT565qRJMnk1TUYzUgwBQBeWQgDmrUEx4rMVsHnpVmF+hB4oA3LeXnrWraz4Iya5yJ8HINX4JiAOeaAOiSbcfSpc84NZVtNngnir8UgA5oAsKcHB6dqkMaSAjp74qAHJA7VNCSWPtQBVeBg2AOPairRBycZx7UUAfGNFFFADl+9V+36Cs9eoq/B2oA0IPer9sec1nwnBHrV63PNAG3b8getXYyazrZuKvxGgC5E2QKnU1WiOOlWF6e9AEyHipFGTUSnipB+dAEgbB6078aYDTjyRxmgCUHinDrTAeaVTzQBYgco4YZHNdppM6ywqDyCK4bPPFb2gXJBVSeR0oA3buDYxx0NUShXpW1JH9ohDDqtZsw2nB4NAEEUe7J7elS7fu4+tMXlsE4qVAAR9aAFlHzlj1qvInrSXzuZyR90HjFLuLqCe1AEJX5SCM1UCfPmrjMD0qNkBIbHNABJhgF9KrucMQTVpQecjmoZF5oAgAw4I6U+TDIaNg46U7bgc80AMthllBORnrWlJgKAKpRLtGRUxYlxmgCaQfugR1pLZHkmA7d6m274vl6YqzbJ5MBJxk0AVdUl2qRzXDa1cb5So7V1GtTFImbPauGuJC8rE+tAEeex6U0sMUxiecHmmZPrxQA/cfpTSfzpN3emluvFAC549qWmFvloU5PNADwAKeORTVPOO1OAOAKAHdqcq96QgZ6U5aAHqBwakXrTF71KnFADwMH9acKQsM4py0AOUU8dKag55qQD04NAC4NSDpzTQDjrTh1oAeozxjNWI1wABmoohznBqz2BoAfGxGQanSTkVU4znmpF+UUAadvNita3m3KAfSucjcjAHSr1vcEEc0AdAh6EH8anSX1NZ9rNvA54q0uMjFAF054waKfDEXTJooA+L6KKKAFXqKu2xNUauW/SgDQj61ftz0rPh7VetzyKANm1JxV+I54zzWbatWhEfagC5F6Z5qyKpxH5hzVpD1oAnTke1PWolPP1qQUAPUkdKkUZ5NRA46VKpOM9qAH5wM05TTFPJFPHSgB4ODVuwl8q5Q9s1SHvTkbBGKAPRNMk3xjBNF3AGPB4rJ0C5zEBnpW/Om+MNmgDIMWH569KSbofUVLP8suKZLgt8p+tAFeRvlHFR5NPk+9x1pr/ADA4PWgCM9elMVsEDtnmjlc0w/kaALYAIOB1qvJ1PGTU8X3BzzTJuuAO1AFfAzyOTTiBjrSHhgtPCZ70ALEvGTwKlVfnxTI+uO3pmpkXDk5oAtQrucKOhqe6/dpgfSn2cfO/Paq2oSALwfagDkvElxiHaOpNcwRnrWvr0pa5xxgdqx2ODQBE/U9qaQO1PA5NIwGfSgBlMYc89KeRio2OTigBpz/9anJ1pVGaco60AKKlUggZqML3pRQBKWzRjtUW496XdzQBPGe3rUoNQKc4wanjHTNAEijPNSoBmmKKlA6gUAKBmngevSmr0xTxgcHpQA5eBinoM9aYuM8HNTgcDnigCSMZH4VNjjgUxAOB608cYFAC+lPXr70KM9qfjmgAAyaepKH8aAOlKoA60AXrW4IIHrW7ZuZCoXrXLLwwIFdL4fBZyewoA6aBAkSjAoqCSYFuGxjiigD4mooooAKtW54qrViA8jmgDSh7GrsB5FUIjV2A9KANa1PFaUXIFZVt1FakR6GgC3HjjFWV6f0qovqKsIScetAFhDx05qVTz7VCvbmpM4agCUc04cjmmCpF6UALnuBUq9PrUXOOlPB9+KAH54pwNNGeM0ueKANfQ5ykxX1rtbdvNgwa85tZPLmU5xzzXeaVNuVcHtQAXMZxux04NV8fNz0Nal1G5+70NZ8oCkDHOfSgCpIuX4qFiF4FTS8sw7VVYkk9aAEPTpSADcKcinueKQjLcCgCZG9R0psvOQc00fL1oZtwoAagDDpkin7DwOnrSrwMGngc0ANjQc44qxGnODRCAxxwKtQrxx345oAswfLAeO1ZuoOArdK1pVxbDtWBqjYRuvrQBwmpvuuX+tUW557VNctm4cj1qBvSgBh4/GgnNKentTDQAhPFNxyaU8c0LzQADk8U8DBGKaKlQDHWgBVyQMUowTjGaDwc0o5oAaVyaTy/1qTZ+FPVeRnrQAkURAqwqEHmnxLxVhQMYoAhXI6DrT1yPxqYAe1OK5oAiXrmnDnHUE0Fe4706PnqaAHIuMCp0wBjr2qNMCnrwOKAJ1HNSqM81CO1WVxigAAx0p4Ax1oPTrSgHZQAq+1O6UwdTTupAoAkhG5gB1JxXUWSi0tgFHLdaydEtvMl3MOFrXnOe3HSgB6yAjJNFRKOOKKAPkCiiigAqWDrUVSRdR9aANKE5FXYe2KowdKuW33hQBq2pPrWnGeBism261pw/dFAF2M8etWYjVSHvVpPuigCwv4VID61BH0/Gp06n6UASDpTh7U0dKcOlAD8kinqR65NRD7wp696AJAfwpQfTNNHSnDr+FADs4+tdboFzujUE9Otcifv/hW/4d6/jQB27EvBnOTWbOMNnBq/b/6o/wC6arS/dagDMl9SMVDKnzfhVmbvUEvQUAVn+UcEj2piyYY5pz96h/iNAFkHdzkUg5JPvTYvun6U89KAHg4Bz3pwHIz+NRj7hp4+6aAJFGSAOgrQtwOme3eqUQ4FXLb75oAuTjbbDcOK5XWpNsbc9q6u+/1K/SuN17/V/hQBxEhwSe5NRFuSKe/Wov4jQAp/Sm0q96aetADD97vinLSHrSj7tADlAp4I6AZpvYU+LpQA4LjmpkHtTT0p8fSgAGMninAc0gpy9aALEQqdQKjj+7U/8AoAADT8frSDvTx96gBClGwhcinp1FOHagCIDPbNShflGDSH7tPTqKAHICOtTIeKaKen3h9KAJF57VIWpI+hpF60AHfinxAs4xnnim/w/hVuwA+0R/WgDobGEW9mv95hzR1681LJ938Kbb/61frQBYjQBBleTzRVs9qKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior view of the right shoulder demonstrates prominent dystrophic calcification within the tendon of the rotator cuff, superior to the humeral head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_39_22143=[""].join("\n");
var outline_f21_39_22143=null;
